A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Phase: PHASE3
Conditions: Psoriasis
Sponsor: Bristol-Myers Squibb

Official Title of Study: 
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study 
to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque 
Psoriasis 
 
NCT Number: NCT03624127 
Document Date (Date in which document was last revised): December 17, 2019 

Protocol Number:
IM011046
IND Number:
131,993
EX-US
Non-IND
EUDRACT Number:
2018-001926-25
Date, Version:
17 Dec 2019, Global Protocol v6.0, 
Revised Protocol 10 Final Approved
Clinical Protocol IM011046 
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled 
Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with 
Moderate-to-Severe Plaque Psoriasis 
Short Title:  Efficacy and Safety of BMS-986165 versus Placebo and Active Comparator in Subjects 
with Psoriasis
Study Director
Medical Monitor
24-hr Emergency Telephone Number 
North America: 
Asia-Pacific: 
Bristol-Myers Squibb Research and Development 
3401 Princeton Pike 
Lawrenceville, NJ 08648 
Avenue de Finlande 4 
B-1420 Braine-l’Alleud, Belgium
6-5-1 Nishi-Shinjuku, Shinjuku-ku,
Tokyo, 163-1328, Japan 
This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates 
(BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of 
assessing whether your organization will participate in and/or the performance of the proposed BMS sponsored study. Any 
permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your 
independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly 
prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be 
added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as 
the contents of this document. Any person who receives this document without due authorization from BMS is requested 
to return it to BMS or promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to 
partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO). 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
2 
DOCUMENT HISTORY 
Document
Date of Issue
Approver(s)
Summary of Change
Original 
Protocol
18-May-2018
Not applicable
Amendment 01
15-Jun-2018
Clarified that Psoriasis 
Symptoms and Signs Diary 
(PSSD) daily data collection 
will begin at the Screening 
Visit and, for randomized 
subjects, will continue daily 
through Week 52.
Amendment 02
17-Jul-2018
Japan-Specific Amendment
Amendment 03
03-Oct-2018
China-Specific Amendment
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
3 
Amendment 04
20-Nov-2018
Updated the Sponsor’s 
contact information, made 
typographic corrections to 
the protocol, clarified 
certain procedures, updated 
wording in Appendix 3 to 
be consistent across studies 
of BMS-986165, described 
treatment assignment 
details, and revised certain 
exclusion criteria to be 
consistent with certain 
elements of the Phase 2 
study of BMS-986165 in 
psoriasis as well as other 
Phase 3 studies in psoriasis
Amendment 05
12-Dec-2018
German-Specific 
Amendment
Amendment 06
14-May-2019
As this is designed to be a 
global study across multiple 
countries, randomization in 
each country will be 
targeted to approximately 
35% or less of the total 
sample size. This change is 
being implemented to 
achieve geographical 
representation across 
countries and to minimize 
the potential for any single 
country to have a 
disproportionate impact on 
the overall efficacy and/or 
safety profile.
Other changes include:
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
4 
-Updated text in the
definition of sPGA in 
Section 8.1.1.1 to be 
consistent with the 
description in Appendix 5. 
 
 
 
 
Amendment 07
06-June-2019
Revised the testing order 
(hierarchy) of key 
secondary endpoints
 
 revised the text 
in the synopsis, Table 4 and 
in Sections 9.3.2.1 and 
9.3.2.2 accordingly as 
follows:
x Removed endpoints 
containing ‘PSSD sign 
score.’ The reason for 
this change is that PSSD 
sign score is redundant 
with components 
assessed by PASI and 
sPGA which are already 
in the hierarchy.
x Removed ‘change from 
baseline in DLQI score.’ 
The reason for this 
change is that DLQI 
endpoint ‘DLQI 0/1 
among subjects with 
baseline DLQI score ≥2’ 
is clinically meaningful 
and is already in the 
hierarchy.
x Changed the 
comparisons to 
apremilast from ‘sPGA 
0/1 at Week 52’, ‘PASI 
75 at Week 52’, and 
‘PASI 90 at Week 52’ to 
‘sPGA 0/1 at Week 52 
and Week 24’, ‘PASI 75 
at Week 52 and Week 
24’, and ‘PASI 90 at
Week 52 and Week 24’.
The reason for these
changes is to assess 
maintenance of effect.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
5 
Amendment 08
24-Jun-2019
China-Specific 
Amendment
Amendment 
09
12-Jul-2019
Germany-Specific 
Amendment – Included 
changes listed above for 
Global Amendments 04, 06
and 07
Global Revised 
Protocol 10
17-Dec-2019
Made the following 
updates:
x
provided clarifications 
in the protocol to aid 
sites and subjects in the 
conduct of the study.
x
added and updated 
relevant protocol 
deviation criteria for the 
Per Protocol Set
x
corrected typographical 
errors
x
added a new analysis 
for systemic treatment-
naïve subjects to the set 
of subgroup analysis for 
the coprimary efficacy 
endpoints
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
6 
SUMMARY OF CHANGES 
Rationale: 
The primary purpose of this global revised protocol is to provide clarifications in the protocol to 
aid sites and subjects in the conduct of the study. 
Key modifications and clarifications are summarized as follows:  
o
Add clarifying detail to several items in the protocol  
o
 
o
Added and updated relevant protocol deviation criteria for the Per Protocol Set 
o
Added a new analysis for systemic treatment-naïve subjects to the set of subgroup analysis 
for the coprimary efficacy endpoints 
Substantive changes made to the previous version of the global protocol and the rationale for these 
changes are noted below in the summary of key changes table. All changes applied to the protocol 
body were applied to the synopsis, as necessary; synopsis changes are not included in the summary 
of key changes table. Only major additions and deletions are provided in this summary document; 
all minor grammatical, formatting, stylistic changes, or clarifications as well as organizational 
changes are not included. 
Protocol Section
Revised Protocol Text
Rationale for Change
Schedule of 
Assessments 
Table 3
Removed Targeted PE from the Week 52 visit
There is already a scheduled Full PE for 
the Week 52 visit.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
7 
Protocol Section
Revised Protocol Text
Rationale for Change
4.1.6.2 Infection 
Adjudication 
Committee
4.1.6.3 CV 
Committee
4.1.6.4 Suicidal 
Ideation and 
Behavior 
Adjudication 
Committee
Updated text to: 
An independent Infection Adjudication Committee, composed of 
individuals with relevant expertise, will blindly review and 
adjudicate infection AEs, such as opportunistic infections, 
influenza, herpes zoster, and TB, reported in the study per
criteria specified in a separate charter.
An independent Cardiovascular (CV) Adjudication Committee,
composed of individuals with relevant expertise, will blindly
review and adjudicate cardiovascular and cerebrovascular AEs 
such as, but not limited to, Major Adverse Cardiovascular Events 
(MACE) that include death, non-fatal myocardial infarction, 
non-fatal stroke; revascularization procedures; heart failure; 
dysrhythmias; heart blocks; and thrombotic events reported in the 
study per criteria specified in a separate charter.
An independent Suicidal Ideation and Behavior Adjudication 
Committee, composed of individuals with relevant expertise, will 
blindly review and adjudicate suicidal ideation/behavior reported 
in the study per criteria specified in a separate charter.
To clarify that the data will be reviewed 
in a blinded manner by the study’s 
Adjudication committees.  
5.3 Lifestyle 
Restrictions
Updated text:
General skin care measures (with above restrictions for topical 
treatments) that are standard for patients with plaque psoriasis are
permitted.
To clarify general skin care measures
used in the trial.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
8 
Protocol Section
Revised Protocol Text
Rationale for Change
6.7.1 Prohibited 
and/or Restricted 
Treatments
Updated or added text:
7) Any use of oral psoriasis medications (eg, methotrexate, 
cyclosporine, retinoids, fumaric acid derivatives) for any 
indication
8) Any use of oral or injectable corticosteroids (prednisone, 
methylprednisolone, etc.), unless it is considered necessary for the 
subject’s welfare and/or treatment of an AE/SAE
Note: otic, ophthalmic, nasal, or inhaled corticosteroids within 
recommended doses and with no systemic effects are 
permitted
9) Any topical medications/treatments, which are used for any 
indication, that could affect psoriasis evaluation (including, but 
not limited to, high potency corticosteroids (WHO Classes I-V), 
>3% salicylic acid, urea, alpha- or beta-hydroxyl acids, anthralin, 
calcipotriene, vitamin D derivatives, retinoids, tazarotene, 
methoxsalen, trimethylpsoralens, pimecrolimus, and tacrolimus)
Exception: The following topical treatments may be initiated only 
at Week 24 per investigator’s discretion in subjects who have 
sPGA scores ≥ 3 (See Section 4.1.4):
•
High potency corticosteroids (WHO Classes I-V), >3% 
salicylic acid, urea, alpha- or beta hydroxyl acids, anthralin, 
calcipotriene, vitamin D derivatives, retinoids, tazarotene
Note: Low potency topical steroids (WHO Classes VI and VII) 
are permitted on the palms, soles, face, and intertriginous 
areas but should not be used within 24 hours prior to any 
study visit. Bland emollients (defined as emollients without 
urea or alpha or beta-hydroxy acids or other ingredients 
which are pharmaceutically active) are allowed on all body 
regions but should not be used within 24 hours prior to any 
study visit.
Added clarifying detail around these 
prohibited medications
6.7.2 Permitted 
Concomitant 
Medications
Note: Low potency topical steroids (WHO Classes VI and VII)
are permitted on the palms, soles, face, and intertriginous areas 
but should not be used within 24 hours prior to any study 
visit. Bland emollients (defined as emollients without urea or 
alpha or beta hydroxy acids or other ingredients which are 
pharmaceutically active) are allowed on all body regions but
should not be used within 24 hours prior to any study visit.
Added clarifying detail around these 
medications
8.4.7 Suicidal 
Ideation and 
Behavior 
Monitoring
Subjects who answer yes to Questions 4 or 5 which indicates a
suicidal ideation severity level of 4 or 5 or document suicidal 
behavior or suicidal attempts on the eC-SSRS will have their 
treatments discontinued and be immediately referred to a mental 
health professional for further evaluation.
Clarified to sites to what levels of 
suicidal ideation Questions 4 and 5 refer.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
9 
Protocol Section
Revised Protocol Text
Rationale for Change
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
10
Protocol Section
Revised Protocol Text
Rationale for Change
9.2 Populations 
for Analyses
Changed to:
Full Analysis Set (FAS):  All subjects who were randomized to 
receive assigned study treatment. Following the intent-to-treat 
principle, subjects will be analyzed according to the treatment 
group assigned at randomization. The FAS will be the primary 
efficacy analysis population.
Per Protocol Set (PPS):  A subset of the FAS who are compliant 
with study treatment and who do not have any relevant protocol 
deviations that may impact the coprimary efficacy endpoint 
assessments (Section 9.6.3). The PPS will be analyzed for the 
coprimary endpoint comparison according to the treatment
assigned at randomization.
As-treated Population:  All randomized subjects who take at least 
one dose of study treatment. Subjects will be analyzed according 
to treatment received. The As-treated population will be for 
safety analyses.
To align populations for testing 
coprimary efficacy endpoints in order 
and to clarify that Per Protocol set will 
be a subset of FAS to assess the 
sensitivity of coprimary endpoints 
results based on FAS with respect to 
data irregularity and deviations
9.4.1.4 Subgroup 
Analyses for the 
Coprimary 
Endpoints
Added: Prior systemic treatment of psoriasis (yes/no)
To determine whether treatment effect 
sizes of BMS-986165 compared to 
placebo are similar or how much 
different with respect to prior use of 
systemic treatment affects
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
11
Protocol Section
Revised Protocol Text
Rationale for Change
9.6.3 Relevant 
Protocol 
Deviations
Changed to:
Relevant protocol deviations are deviations that can have an 
impact on the primary efficacy endpoints. The impact of 
relevant protocol deviations on the primary efficacy results will 
be assessed by excluding subjects from the FAS to define the PPS 
in supportive analyses of the primary efficacy endpoints. 
Relevant protocol deviations to be considered regarding exclusion 
of subjects from the FAS will include the following:
Subject randomized but did not take any study treatment
Subject failed to meet study inclusion criteria but was 
randomized to receive study treatment
Subject met a study exclusion criterion which may have an 
impact on the coprimary efficacy endpoints but was 
randomized to receive study treatment
Subject non-compliant with study treatment within the first 
16 weeks of treatment; defined as <80% compliant with study 
treatment 
Subject took prohibited concomitant medication prior to 
Week 16
Subject received treatment different to intended treatment at 
any visit prior to Week 16
All subjects with relevant protocol deviations will be identified 
prior to database lock. Relevant protocol deviations will be 
summarized by treatment group and deviation category for 
the FAS population.
To clarify and document the final list of 
relevant protocol deviations for Per 
Protocol Analysis.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
12
TABLE OF CONTENTS 
TITLE PAGE ...................................................................................................................................1
DOCUMENT HISTORY.................................................................................................................2 
SUMMARY OF CHANGES ...........................................................................................................6 
TABLE OF CONTENTS ...............................................................................................................12 
1 
PROTOCOL SUMMARY ..........................................................................................15 
1.1 
Synopsis ......................................................................................................................15 
1.2 
Schema ........................................................................................................................20 
1.3 
Schedule of Activities (SOA) .....................................................................................20 
2 
INTRODUCTION ......................................................................................................33 
2.1 
Study Rationale ...........................................................................................................33 
2.2 
Background .................................................................................................................34 
3 
OBJECTIVES AND ENDPOINTS ............................................................................36 
4 
STUDY DESIGN .......................................................................................................38 
4.1 
Overall Design ............................................................................................................38 
4.2 
Number of Subjects ....................................................................................................42 
4.3 
End of Study Definition ..............................................................................................42 
4.4 
Scientific Rationale for Study Design ........................................................................42 
5 
STUDY POPULATION .............................................................................................43 
5.1 
Inclusion Criteria ........................................................................................................44 
5.2 
Exclusion Criteria .......................................................................................................44 
5.3 
Lifestyle Restrictions ..................................................................................................49 
5.4 
Screen Failures ............................................................................................................49 
6 
TREATMENT ............................................................................................................50 
6.1 
Treatments Administered ............................................................................................52 
6.2 
Method of Treatment Assignment ..............................................................................52 
6.3 
Blinding ......................................................................................................................53 
6.4 
Dosage Modification ..................................................................................................54 
6.5 
Preparation/Handling/Storage/Accountability ............................................................54 
6.6 
Treatment Compliance ................................................................................................55 
6.7 
Concomitant Therapy .................................................................................................55 
6.8 
Treatment After the End of the Study .........................................................................57 
7 
DISCONTINUATION CRITERIA ............................................................................57 
7.1 
Discontinuation from Study Treatment ......................................................................57 
7.2 
Discontinuation from the Study ..................................................................................59 
7.3 
Lost to Follow-Up.......................................................................................................59 
8 
STUDY ASSESSMENTS AND PROCEDURES ......................................................59 
8.1 
Efficacy Assessments .................................................................................................60 
8.2 
Adverse Events ...........................................................................................................65 
8.3 
Overdose .....................................................................................................................68 
8.4 
Safety ..........................................................................................................................68 
8.7 
Health Economics OR Medical Resource Utilization and Health Economics ...........76 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
13
9 
STATISTICAL CONSIDERATIONS .......................................................................76 
9.2 
Populations for Analyses ............................................................................................76 
9.3 
Endpoints ....................................................................................................................77 
9.4 
Efficacy Analyses .......................................................................................................81 
9.5 
Safety Analyses ..........................................................................................................85 
9.6 
Other Analyses ............................................................................................................86 
9.7 
Interim Analyses .........................................................................................................87 
10 
REFERENCES ...........................................................................................................88 
11 
APPENDICES ............................................................................................................92 
APPENDIX 1 
ABBREVIATIONS AND TRADEMARKS .............................................93 
APPENDIX 2 
STUDY GOVERNANCE CONSIDERATIONS ......................................97 
APPENDIX 3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING .............................105 
APPENDIX 4 
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS 
AND METHODS OF CONTRACEPTION ............................................109 
APPENDIX 5 
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF 
PSORIASIS (sPGA) ................................................................................113 
APPENDIX 6 
PSORIASIS AREA AND SEVERITY INDEX (PASI) ..........................114 
APPENDIX 7 
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA) ..................................................................................................115 
APPENDIX 9 
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS (PGA-
F) ..............................................................................................................117 
APPENDIX 11 
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA) .......................................................................120 
APPENDIX 13 
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD) .....................122 
APPENDIX 14 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) ............................123 
 
 
 
 
 
 
APPENDIX 21 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE ....................................................................145 
APPENDIX 22 
EIGHT-ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8) ........146 
APPENDIX 23 
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS .........................................................................................147 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
14
LIST OF TABLES 
Table 1: 
Screening Procedural Outline (IM011046) ................................................21 
Table 2: 
On Treatment Procedural Outline (IM011046): Week 0 through 
Week 20 .....................................................................................................24 
Table 3: 
On Treatment Procedural Outline (IM011046): Week 24 through 
Week 52 .....................................................................................................28 
Table 4: 
Objectives and Endpoints ..........................................................................36 
Table 5: 
Study Treatments for IM011046 ................................................................51 
Table 6: 
Selection and Timing of Dose....................................................................52 
LIST OF FIGURES 
Figure 1: 
Study Design Schematic ............................................................................41 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
15
1 
PROTOCOL SUMMARY 
1.1 
Synopsis 
Protocol Title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-
Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with 
Moderate-to-Severe Plaque Psoriasis
Short Title: Efficacy and Safety of BMS-986165 versus Placebo and Active Comparator in Subjects 
with Psoriasis
Study Phase: 3
Rationale: 
BMS-986165 is being evaluated as a therapeutic option for the treatment of subjects with 
moderate-to-severe plaque psoriasis based on results of a recently completed 12-week,
randomized, Phase 2, placebo-controlled, parallel-group study (Study IM011011). The Phase 2 
study was conducted with the following 5 different BMS-986165 treatment arms: 3 mg every other 
day (QOD); 3 mg once daily (QD); 3 mg twice daily (BID); 6 mg BID; and 12 mg QD. Overall, 
267 subjects were randomized (44 to 45 subjects per treatment arm) in the Phase 2 study. All 
BMS-986165 treatment groups, except 3 mg QOD, achieved the primary endpoint of superiority 
compared with placebo in the proportion of subjects experiencing at least a 75% improvement in 
the Psoriasis Area and Severity Index (PASI 75) after 12 weeks of treatment. Compared with the 
placebo treatment group (6.7%), 38.6% (p = 0.0003), 68.9% (p < 0.0001), 66.7% (p < 0.0001) and 
75% (p < 0.0001) of the subjects treated with BMS-986165 at 3 mg QD, 3 mg BID, 6 mg BID and 
12 mg QD doses achieved a PASI 75 response, respectively. The PASI 75 responses appear to 
plateau at the dose of 3 mg BID. The current Phase 3 study is designed to confirm the efficacy and 
safety of BMS-986165 6 mg QD which is expected to have equivalent efficacy as the 3 mg BID 
dose in Phase 2, in a larger global population of subjects with stable moderate-to-severe plaque 
psoriasis.  
Study Population: 
Men and women ≥18 years of age diagnosed with stable (defined as no morphology changes or 
significant flares of disease activity in the opinion of the investigator) plaque psoriasis for ≥6 
months and with moderate-to-severe disease by involvement of ≥10% of body surface area (BSA), 
static Physician’s Global Assessment (sPGA) ≥3, PASI score ≥12, and candidates for phototherapy 
or systemic therapy will be eligible to participate in the study.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
16
Objectives and Endpoints: 
Objective
Endpoint
Primary
x
Assess whether BMS-986165 is superior 
to placebo at Week 16 in the treatment of 
subjects with moderate-to-severe plaque 
psoriasis
x
sPGA 0/1
x
PASI 75
Selected Secondary Endpoints
x
Assess whether BMS-986165 is superior 
to apremilast at Week 16
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Assess whether BMS-986165 is superior 
to apremilast at Week 52
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Assess whether BMS-986165 is superior 
to placebo over the first 16 weeks of 
treatment
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Assess whether BMS-986165 is superior 
to apremilast over 52 weeks of treatment
x
sPGA 0/1
x
PASI 75
x
PASI 90
x
sPGA 0
x
PASI 100
x
Evaluate 
improvement 
in 
patient-
reported outcomes for BMS-986165
compared with placebo through Week 16
x
Evaluate 
improvement 
in 
patient-
reported outcomes for BMS-986165
compared 
with 
apremilast 
through 
Week 24
x
Change from baseline in Psoriasis 
Symptoms and Signs Diary (PSSD) 
symptom score, sign score, and total 
score
x
Change from baseline in Dermatology 
Life Quality Index (DLQI) score
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
17
Objective
Endpoint
Overall Design: 
This will be a 52-week, multi-center, randomized, double-blind, double-dummy, placebo- and 
active comparator-controlled study in subjects with stable moderate-to-severe plaque psoriasis. 
Subjects will undergo screening evaluations within 28 days prior to administration of study 
medication to determine eligibility. Following the screening process, approximately 600 qualified 
subjects will be randomized in a 2:1:1 ratio to one of the following 3 treatment groups: 
x
BMS-986165 6 mg QD 
x
Placebo 
x
Apremilast 30 mg BID (with initial titration per label) as active comparator 
Randomization should not occur until at least 8 days after the Screening Visit to allow collection 
of PSSD data during screening in order to calculate a baseline PSSD score. Randomization will be 
stratified by geographic region (U.S., Japan [body weight stratum will not be applied in Japan], 
China [body weight stratum will not be applied in China], and Rest of World), previous biologic 
use (for psoriasis, psoriatic arthritis or other inflammatory diseases only; yes/no), and body weight 
(≥90 kg and <90 kg). If subjects from China are not enrolled in the study, then the stratification 
level for China will not be utilized. As this is designed to be a global study across multiple 
countries, randomization in each country will be targeted to approximately 35% or less of the total 
sample size. This change is being implemented to achieve geographical representation across 
countries and to minimize the potential for any single country to have a disproportionate impact 
on the overall efficacy and/or safety profile. 
At Week 16, subjects receiving placebo will be switched in a blinded manner to BMS-986165 
6 mg QD. Subjects who are randomized to BMS-986165 6 mg QD or apremilast 30 mg BID will
continue their current dose through Week 52.  
At Week 24, subjects originally randomized to apremilast 30 mg BID who do not achieve PASI 50 
response will be switched in a blinded manner to BMS-986165 6 mg QD; those who achieve 
PASI 50 response will continue to receive their current regimen through Week 52. A subject with 
sPGA ≥3 at Week 24 may be treated with restricted topical medications, such as topical high 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
18
potency corticosteroids (WHO Classes I-V), only at this time point at the discretion of the 
investigator. 
Subjects who discontinue study treatment early should remain in the study for protocol-specified 
procedures (Please refer to Section 7.1 for more details). Those completing 52 weeks of treatment 
will be offered the opportunity to roll over to a separate long-term extension study (≥2 years) and 
be treated with open-label BMS-986165 6 mg QD. 
Treatment Arms and Duration: 
Study treatment: Subjects in all treatment groups will take oral doses of the investigational 
product (IP) for 52 weeks during treatment as follows: BMS-986165 6 mg QD, apremilast 30 mg 
BID (titrated as per label), or placebo QD.
Study Treatment for IM011046
Medication 
Potency 
IP/Non-IP 
BMS-986165 tablet
6 mg
IP
apremilast tablet
10 mg*
IP
apremilast tablet
20 mg†
IP
apremilast tablet
30 mg‡
IP
placebo tablet
n/a
IP
IP = investigational product; n/a = not applicable 
*Used for titration Day 1 through Day 3 morning dose 
†Used for titration Day 3 evening dose through Day 5 morning dose. 
‡From Day 5 evening dose onwards 
Statistical Methods 
General Methodology 
The primary efficacy analysis population will be the Full Analysis Set (FAS). The FAS will 
include all randomized subjects who are dispensed study drug.  
The analysis model for the coprimary efficacy endpoints and secondary binary endpoints will use 
stratified Cochran-Mantel-Haenszel (CMH) tests stratified by the factors used for randomization 
(see Sec. 4.1.2) to compare the response rates of BMS-986165 6 mg QD to placebo or apremilast 
as applicable. If expected cell counts are not sufficient for each strata level, then strata levels will 
be combined for the analysis. Nonresponder imputation will be used for binary endpoints for 
subjects who discontinue study or treatment of study prior to Week 16, start a protocol prohibited 
medication/therapy that could improve psoriasis during the first 16 weeks of treatment, or who 
have otherwise missing endpoint data at the specified timepoint. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
19
The analysis model for continuous secondary endpoints will use analysis of covariance 
(ANCOVA) with treatment and the factors used for randomization as fixed effects. The baseline 
value will be added into the model as a covariate. Treatment differences based on least-squares 
(LS) means and the corresponding 2-sided 95% confidence intervals (CIs) will be provided for the 
difference between BMS-986165 6 mg QD and placebo or apremilast depending on the endpoint 
being assessed. 
Testing Strategy for Efficacy Endpoints 
The primary family of coprimary endpoints will each be tested at a Type I error=0.05 first, and if 
significant for both endpoints, testing will proceed for the secondary family of key secondary 
endpoints 
. The primary family of coprimary endpoints will be the serial gatekeeper for 
proceeding with testing of the secondary family of key secondary efficacy endpoints. 
Primary Family – Coprimary endpoints compared with placebo; both must be significant at a Type 
I error=0.05 in order to proceed with the secondary family tests for the key secondary endpoints:  
x
Primary 1: Proportion of subjects who achieve sPGA 0/1 at Week 16 
x
Primary 2: Proportion of subjects who achieve PASI 75 at Week 16 
In order to control for Type I error rate inflation within the secondary family of key secondary 
endpoints, separate testing branches with a 2-sided Type I error=0.025 will be used for 
comparisons of BMS-986165 6 mg QD compared to placebo and BMS-986165 6 mg QD 
compared to apremilast. A hierarchical testing method within each testing branch will be 
implemented for the key secondary endpoints. The hierarchical test may only proceed to the next 
key secondary endpoint within each testing branch if the null hypothesis is rejected a Type I 
error=0.025. If an endpoint fails at any step, then all subsequent p-values will be considered 
descriptive. 
Safety Analysis 
Safety data will be summarized using descriptive statistics (n, mean, standard deviation, median, 
minimum, and maximum) for continuous variables and frequency distributions (counts and 
percentages) for categorical variables. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
20
1.2 
Schema 
*Apremilast is titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing 
Abbreviations: BID = twice daily; QD = once daily; R = randomize 
The coprimary endpoints will be evaluated at Week 16. The duration of the study for each 
subject will be up to 52 weeks on treatment and 4 additional weeks for safety follow-up. 
1.3 
Schedule of Activities (SOA) 
The schedules of assessments and procedures are documented in Table 1 for screening, Table 2 
for baseline through Week 20, and Table 3 for Week 24 through Week 52. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
21
Table 1:
Screening Procedural Outline (IM011046)
Procedure
Screening
V1
Notes
Eligibility Assessments
Informed Consent
X
A subject is considered enrolled only when a protocol-specific 
informed consent is signed
Enroll Subject
X
Obtain number from IRT
Inclusion/Exclusion Criteria
X
Includes duration of plaque psoriasis and documentation of presence 
of plaque psoriasis by the investigator
Medical History
X
See Section 5.2 for complete eligibility criteria associated with 
medical history. Of note, subjects need to be screened for any current 
uncontrolled neuropsychiatric illness or history of suicidality; any 
history of TB; any congenital or acquired immunodeficiency; any 
significant drug allergy such as anaphylaxis; any cancer currently or 
in the previous 5 years. Investigators are encouraged to check 
whether subjects have had preventive health measures such as cancer 
screening (e.g. Pap smear, colonoscopy, mammograms) that is up to
date according to local guidelines
History of Tobacco Use
X
Include description of current tobacco use
Psoriasis-related History
X
Includes scalp symptoms, PsA/joint pain, nail involvement, 
palmoplantar involvement, genital involvement, history of other 
forms of psoriasis
Psoriasis-related Systemic Treatment
X
History of: conventional systemic (eg, methotrexate), biologic, and/or 
phototherapy. For each therapy, include length of time on treatment 
and reason(s) for discontinuation (eg, lack of efficacy, intolerance, 
side effects, loss of access to treatment) if applicable. 
Other Prior and Concomitant Treatments
X
Includes topical treatments and shampoos for psoriasis and all 
medications for other conditions such as cardiovascular and mood 
disorders
Safety Assessments
Physical Examination
X
Complete PE
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
22
Table 1:
Screening Procedural Outline (IM011046)
Procedure
Screening
V1
Notes
Physical Measurements
X
Includes height and weight
Vital Signs
X
Includes (ear or oral) body temperature, respiratory rate, seated blood 
pressure and heart rate. Blood pressure and heart rate should be 
measured after the subject has been resting quietly for at least 5 
minutes.
Electrocardiogram
X
ECGs should be recorded after the subject has been supine for at least 
5 minutes
Chest Imaging (eg, Chest x-ray)
X
Chest imaging is required if not performed within 6 months of 
Screening Visit, copy of radiology report must be on file and 
reviewed by the investigator. Section 8.4.4
Neuropsychiatric Illness Assessment
X
Based on subject/family response, medical history/medical records, 
investigator judgment
PHQ-8
X
For establishing baseline depression severity
Suicidal Ideation and Behavior Assessment
X
Based on subject/family response, medical history/medical records, 
investigator judgment
eC-SSRS
X
eC-SSRS Assessment: Response of “Actual Suicide Attempt-
Lifetime” or suicidal ideation (Severity of 4 or 5) or suicidal behavior 
will be exclusionary. Rescreening will not be allowed. Section 8.4.7
Monitor for SAEs
X
All SAEs must be collected from the date of subject’s written consent 
until 30 days post discontinuation of dosing or subject’s participation 
in the study.
Laboratory Tests
Hematology
X
Complete Blood Count (CBC) with differential
Chemistry Panel
X
Lipid Panel
X
Urinalysis
X
Hemoglobin A1C
X
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
23
Table 1:
Screening Procedural Outline (IM011046)
Procedure
Screening
V1
Notes
TSH
X
If TSH above normal reference range, test free T4; if TSH below 
normal range, test free T4 & T3
hs-CRP
X
Serology
X
Includes HCV antibody, HBsAg, HBsAb, HBcAb, HBV DNA, and 
HIV antibodies
TB Test
X
In accordance with QuantiFERON-TB Gold. (details described in 
Section 8.4.4).
Pregnancy Test (serum)
X
For WOCBP only
FSH
X
To confirm menopausal status (see APPENDIX 4)
Clinical Efficacy/Health Outcomes
sPGA
X
PASI
X
BSA
X
PASE Questionnaire
X
For subjects with peripheral joint complaints to screen for presence of 
psoriatic arthritis
PSSD
X
All consented subjects will be given a diary device at the Screening 
Visit and will begin recording psoriasis signs and symptoms on a 
daily basis in the diary device. Subjects who are not randomized will 
stop recording and return their diary device to the site. Subjects who 
are randomized will continue recording their psoriasis signs and 
symptoms on a daily basis in the diary device through Week 52.
BSA = body surface area; CBC = complete blood count; DNA = deoxyribonucleic acid; ECG = electrocardiogram; eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; 
FSH = follicle-stimulating hormone; HBV = hepatitis B virus; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; 
HCV = hepatitis C virus; HIV = human immunodeficiency virus; hs-CRP = high-sensitivity C-reactive protein; IRT = interactive response technology; PASE = psoriatic arthritis 
screening and evaluation; PASI = Psoriasis Area and Severity Index; PE = physical examination; PHQ-8 = eight-item Patient Health Questionnaire; PsA = psoriatic arthritis; 
PSSD = Psoriasis Symptoms and Signs Diary; SAE = serious adverse events; sPGA = static Physician Global Assessment; T3 = triiodothyronine; T4 = thyroxine; TB = 
tuberculosis TSH = thyroid-stimulating hormone; V = visit; WOCBP = women of childbearing potential
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
24
Table 2:
On Treatment Procedural Outline (IM011046): Week 0 through Week 20
Procedure
Week 0
Baseline/D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
Clinical Efficacy/Health 
Outcomes
DLQI
X
X
X
X
X
X
X
sPGA
X
X
X
X
X
X
X
X
PASI 
X
X
X
X
X
X
X
X
ss-PGAa
X
X
X
X
X
X
X
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
25
Table 2:
On Treatment Procedural Outline (IM011046): Week 0 through Week 20
Procedure
Week 0
Baseline/D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
PGA-Fb
X
X
X
X
X
Palmoplantar PGAc
X
X
X
X
X
X
X
PSSD
Safety Assessments
Complete PE
X
X
Targeted PE
X
X
X
X
X
X
See Section 8.4.1
Body Weight
X
X
X
Vital Signs
X
X
X
X
X
X
X
X
ECG
X
X
PHQ-8
X
X
X
See Section 
8.4.6.1
eC-SSRS Assessment
X
X
X
Suicidal Ideation 
and Behavior 
since last visit
Adverse Event (AE) Assessment
X
X
X
X
X
X
X
X
Concomitant Medication Use
X
X
X
X
X
X
X
X
Laboratory Tests
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
26
Table 2:
On Treatment Procedural Outline (IM011046): Week 0 through Week 20
Procedure
Week 0
Baseline/D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
Hematology 
X
X
X
X
X
X
X
X
Lymphocyte Subsets (TBNK)
X
X
X
Chemistry Panel
X
X
X
X
X
X
X
X
If CK >2.5 × 
ULN, reflex 
testing is required 
(see Section 8.4.5)
Hemoglobin A1C
X
X
hs-CRP
X
X
X
X
X
X
X
Fasting Lipid Panel
X
X
X
Fasting Plasma Glucose
X
X
X
Urinalysis
X
X
Serum Immunoglobulin Levels 
(IgM, IgG, IgA, IgE)
X
X
X
Pregnancy Test (Urine)
X
X
X
X
X
X
WOCBP only
Study Treatment
Randomize
X
Dispense Study Treatment
X
X
X
X
X
X
X
Study Treatment Compliance
X
X
X
X
X
X
X
See Section 6.6
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
27
Table 2:
On Treatment Procedural Outline (IM011046): Week 0 through Week 20
Procedure
Week 0
Baseline/D1
V2
Week 1
D8
(±3 d)
V3
Week 2
D15
(±3 d)
V4
Week 4
D29
(±3 d)
V5
Week 8
D57
(±3 d)
V6
Week 12
D85
(±3 d)
V7
Week 16
D113
(±3 d)
V8
Week 20
D141
(±3 d)
V9
Notes
 eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; CK = creatine kinase; 
 D = Day; d = days; DLQI = Dermatology Life 
Quality Index; 
; ECG = electrocardiogram; eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; 
 
 hs-CRP = high-sensitivity C-reactive protein; Ig = immunoglobulin; 
 
 PASI = Psoriasis Area and Severity Index; PE = physical examination; PGA = Physician Global Assessment; PGA-F = Physician Global Assessment-Fingernails; 
 
 PHQ-8 = eight-item Patient Health Questionnaire; 
 PSSD = Psoriasis 
Symptoms and Signs Diary; 
 sPGA = static Physician Global Assessment; 
ss-PGA = scalp specific Physician’s Global Assessment; TBNK = T cells, B cells, and natural killer cells; ULN = upper limit of normal; V = visit; 
 Wk = 
Week; 
 WOCBP = women of childbearing potential 
 
bIn subjects with nail psoriasis at baseline 
cIn subjects with palmoplantar psoriasis at baseline 
dIf sample is missed, it may be taken at any visit once informed consent is obtained.
When multiple assessments are conducted at a single visit, the following is the order in which they should be done: 
1)
Health outcomes assessments 
2)
Safety assessments (eg, vitals, AEs) 
3)
Clinical efficacy assessments 
4)
Laboratory tests (eg, safety laboratory tests, 
) 
On fasting days, safety assessments can be done first followed by blood draws, and then health outcomes and finally efficacy assessments. 
The dose of the drug on a visit day is to be taken after blood draws.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
28
Table 3:
On Treatment Procedural Outline (IM011046): Week 24 through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52a
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Upb
(Week 56)
D393
(±3 d)
V18
Notes
Clinical Efficacy/Health 
Outcomes
sPGA
X
X
X
X
X
X
X
X
PASI
X
X
X
X
X
X
X
X
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
29
Table 3:
On Treatment Procedural Outline (IM011046): Week 24 through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52a
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Upb
(Week 56)
D393
(±3 d)
V18
Notes
Safety Assessments
Full PE
X
X
X
Targeted Physical 
Examination
X
X
X
X
X
X
Body Weight
X
X
X
X
Vital Signs
X
X
X
X
X
X
X
X
X
ECG
X
X
PHQ-8
X
X
X
See Section 8.4.6.1
eC-SSRS
X
X
X
Suicidal Ideation and 
Behavior since last visit
AE Assessment
X
X
X
X
X
X
X
X
X
Concomitant Medication 
Use
X
X
X
X
X
X
X
X
X
Laboratory Tests
Hematology 
X
X
X
X
X
X
X
X
X
Lymphocyte Subsets 
(TBNK)
X
X
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
30
Table 3:
On Treatment Procedural Outline (IM011046): Week 24 through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52a
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Upb
(Week 56)
D393
(±3 d)
V18
Notes
Chemistry Panel
X
X
X
X
X
X
X
X
X
If CK >2.5 × ULN, reflex 
testing is required (see 
Section 8.4.5)
Fasting Lipid Panel
X
X
Subjects are required to 
fast for at least 10 hours 
prior to collection
Fasting Plasma Glucose
X
X
hs-CRP
X
X
X
Hemoglobin A1C
X
X
Urinalysis
X
X
X
Serum Immunoglobulin 
Levels (IgM, IgG, IgA, IgE)
X
X
Pregnancy Test (Urine)
X
X
X
X
X
X
X
X
X
WOCBP Only
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
31
Table 3:
On Treatment Procedural Outline (IM011046): Week 24 through Week 52
Procedure
Week 24
D169
(±3 d)
V10
Week 28
D197
(±3 d)
V11
Week 32
D225
(±3 d)
V12
Week 36
D253
(±3 d)
V13
Week 40
D281
(±3 d)
V14
Week 44
D309
(±3 d)
V15
Week 48 
D337
(±3 d)
V16
Week 52a
(or early 
DC)
D365
(±3 d)
V17
Safety 
Follow-Upb
(Week 56)
D393
(±3 d)
V18
Notes
Study Treatment
Blinded PASI Response 
Transferred Electronically 
to IRT
X
To determine PASI 50
response at Week 24
Dispense Study Treatment
X
X
X
X
X
X
X
Study Treatment 
Compliance
X
X
X
X
X
X
X
X
BMI = body mass index; 
 eC-SSRS = electronic Columbia-Suicide Severity Rating Scale; CK = creatine kinase; 
 
 hs-CRP = High-sensitivity C-reactive protein; IRT = 
interactive response technology; 
 PASI = Psoriasis Area and Severity Index; 
 
 PHQ-8 = eight-item Patient Health Questionnaire; 
 
 sPGA = static Physician Global Assessment; 
 
 TBNK = T cells, 
B cells, and natural killer cells; ULN = upper limit of normal; Wk = Week; 
 WOCP = women of childbearing potential 
aFor subjects who discontinue study treatment prior to Week 52, please refer to Section 7.1 for more details.  
bFor subjects who do not continue in a long-term extension study 
When multiple assessments are conducted at a single visit, the following is the order in which they should be done: 
1)
Health outcomes assessments 
2)
Safety assessments (eg, vitals, AEs) 
3)
Clinical efficacy assessments  
4)
Laboratory tests (eg, safety laboratory tests, 
) 
On fasting days, safety assessments can be done first followed by blood draws, and then health outcomes and finally efficacy assessments. 
The dose of the drug on a visit day is to be taken after blood draws. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
32
STUDY ACKNOWLEDGMENT/DISCLOSURE
I understand that this protocol contains information that is confidential and proprietary to Bristol-Myers Squibb 
Company (BMS). Any supplemental information that may be added to this document is also confidential and 
proprietary to BMS and must be kept in confidence in the same manner as the contents of this protocol. 
I have read the original protocol/revised protocol and agree that it contains all necessary details for carrying out the 
study as described.  I will conduct this protocol as outlined therein and will make a reasonable effort to complete the 
study within the time designated. 
I will provide copies of the protocol and access to all information furnished by BMS to study personnel under my 
supervision.  I will discuss this material with them to ensure that they are fully informed about the investigational 
product and the study.   
I will provide protocol information to my Institutional Review Board(s) [IRB(s)] or Independent Ethics Committee(s) 
[IEC(s]. I understand that original protocol/revised protocols must be reviewed by the Institutional Review Board or 
Independent Ethics Committee overseeing the conduct of the study and approved or given favorable opinion by all 
necessary health authorities before implementation unless to eliminate an immediate hazard to subjects. 
I agree that the contents of the protocol may not be disclosed to any other person or entity or used for any other purpose 
without the prior written consent of BMS. The foregoing shall not apply to disclosure required by governmental 
regulations or laws; however, I will give prompt notice to BMS of any such disclosure. 
I agree that the study data derived from this protocol may only be used and disclosed in furtherance of the protocol, 
for the medical treatment of a study subject or for publication of study results in accordance with the terms of the 
clinical trial agreement or as otherwise permitted by the terms of the clinical trial agreement. 
I agree not to collect or use samples (eg, tissue, blood, serum, urine) or collect data (other than for diagnostic or 
treatment purposes) from the study subjects while enrolled in the study, except as expressly permitted by the protocol 
or the terms of the clinical trial agreement. 
I understand that I may terminate or suspend enrollment of the study at any time if it becomes necessary to protect the 
best interests of the study subjects. Unless otherwise provided in the clinical trial agreement, the study may be 
terminated at any time by BMS, with or without cause. 
Original Protocol  
Revised Protocol  
Protocol Number: IM011046 
Site Number:  
 
 
Date of Protocol or Revised Protocol:  17 Dec 2019 
 
IND Number:  131,993 
 EUDRACT Number:   2018-001926-25
Investigator  
Date 
(signature) 
__________________________________________________   
(printed name*) 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
33
2 
INTRODUCTION 
Psoriasis is a chronic inflammatory skin disorder, characterized primarily by erythematous scaly 
plaques, that affects up to 3% of the general population. Men and women are equally affected and 
it can present at any age.1,2 Several studies have observed a bimodal distribution of psoriasis onset 
with the first peak ranging from 15 to 22 years of age, and the second peak ranging from 55 to 60 
years of age.3, 4, 5 The most common form of psoriasis (58% to 97% of cases) is plaque psoriasis 
(psoriasis vulgaris), with less common forms being guttate, pustular, inverse (flexural), and 
erythrodermic psoriasis. The disease can have a fluctuating relapsing course, with flares that may 
be induced by factors such as infections, trauma, smoking, and stress.3 Psoriasis can involve skin 
in any part of the body; particularly disabling is the involvement of specific anatomic regions, such 
as hands and feet (palmoplantar), face, scalp, and nails. Disease severity can be classified by body 
surface area (BSA) involvement with mild defined as ≤10% BSA, and moderate-to-severe as 
>10% BSA.6 Psoriasis has a profound impact on quality of life and can lead to psychological, 
social and economic consequences, especially in moderate-to-severe disease. This condition is also 
associated with an increased risk of depression, occurrence of sleep disturbances, social stigma, 
and decreased work productivity.7,8 Commonly associated comorbidities found in psoriasis 
patients include diabetes mellitus and metabolic syndrome. In patients with more severe forms of 
the disease, life expectancy is decreased due to an increase of cardiovascular risk.9
Treatments include topical preparations, eg, corticosteroids, vitamin D analogues, calcineurin 
inhibitors, and salicylic acid; phototherapy modalities, including PUVA (psoralens with UVA) and 
narrow band UVB; and systemic therapies. In moderate-to-severe disease, systemic treatments are 
usually needed and may include oral agents (retinoids, methotrexate, cyclosporine, and apremilast) 
or injectables (eg, biologics such as tumor necrosis factor (TNF) inhibitors etanercept, infliximab, 
and adalimumab) anti-IL-12/23p40 antibody (ustekinumab), IL-17 antagonists (secukinumab, 
ixekizumab, and brodalumab), and anti-IL-23p19 antibody (guselkumab). Many of these 
treatments are associated with increased risk of adverse events (AEs) such as hepatotoxicity and 
neutropenia (methotrexate);10 nephrotoxicity (cyclosporine);11 depression and weight loss 
(apremilast);12 serious infections (cytokine inhibitors);13,14,15,16 candidiasis and Crohn’s disease 
(IL-17 antagonists).16, 17, 18
Although effective therapeutic options are available, under-treatment or nontreatment of psoriasis 
has been reported in up to half of surveyed patients (based on absence of treatment and/or 
dissatisfaction with treatment).19 Many patients with severe disease are still being managed with 
only topicals,4,8 and many patients consider their psoriasis treatment to be inadequate. 
Accordingly, there remains a need for more effective oral options, when compared with currently 
available agents, that would improve efficacy responses and increase adherence to treatment. 
2.1 
Study Rationale 
BMS-986165 could be a therapeutic option for the treatment of subjects with moderate-to-severe 
plaque psoriasis based on results of a recently completed 12-week, randomized, Phase 2, placebo-
controlled, parallel-group study with 5 different BMS-986165 treatment arms: 3 mg every other 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
34
day (QOD); 3 mg once daily (QD); 3 mg twice daily (BID); 6 mg BID; and 12 mg QD (Study 
IM011011). Overall, 267 subjects were randomized (44 to 45 subjects per treatment arm) in the 
Phase 2 study. All BMS-986165 treatment groups, except 3 mg QOD, achieved the primary 
endpoint of superiority compared with placebo in the proportion of subjects achieving PASI 75
after 12 weeks of treatment. Compared with placebo treatment group, in which 6.7% of the subjects 
achieved PASI 75 response, 38.6% (P = 0.0003), 68.9% (P < 0.0001), 66.7% (P < 0.0001) and 
75% (P < 0.0001) of subjects treated with 3 mg QD, 3 mg BID, 6 mg BID, and 12 mg QD achieved 
PASI 75, respectively. The PASI 75 responses plateaued at a dose of 3 mg BID. Also, there was a 
clinically significant proportion of subjects treated with BMS-986165 achieving an sPGA score of 
0 or 1 compared with placebo at Week 12. Compared with the placebo treatment group in which 
6.7% of the subjects achieved an sPGA score of 0 or 1, 41.5%, 75.6%, 65.9%, and 75% of the 
subjects treated with 3 mg QD, 3 mg BID, 6 mg BID, and 12 mg QD achieved an sPGA score of 
0 or 1, respectively with responses again plateauing at dose of 3 mg BID. The Phase 3 dose selected 
(6 mg QD) is expected to demonstrate equivalent efficacy to the 3 mg BID dose. Please refer to 
 
This Phase 3 study is designed to confirm the efficacy and safety of BMS-986165 6 mg QD and 
demonstrate its superiority to a widely used oral agent, apremilast, in a larger global population of 
subjects with moderate-to-severe plaque psoriasis.  
2.2 
Background 
Tyrosine kinase 2 (TYK2) is a nonreceptor tyrosine kinase associated with receptors for the 
p40-containing cytokines IL-12 and IL-23, as well as the Type I interferon (IFN) receptor, and is 
required for the activation of their downstream signaling pathways. TYK2 catalyzes the 
phosphorylation of the intracellular receptor domains and signal transducer and activator of 
transcription (STAT) proteins resulting in the activation of STAT-dependent transcription and 
functional responses specific for these cytokines.20,21,22 Because TYK2-dependent cytokines (eg, 
Type I IFNs, IL-12, IL-23) are distinct from those dependent on closely related Janus kinase (JAK) 
family members JAK1/JAK3 (eg, IL-2, IL-15, IL-7) or JAK2 (eg, erythropoietin, thrombopoietin, 
GM-CSF), a TYK2 inhibitor would be expected to have a highly differentiated profile from 
inhibitors of other JAK family kinases. TYK2-dependent pathways and the cytokine networks they 
modulate (eg, IL-23/IL-17, IFNα) have been implicated in the pathophysiology of multiple 
immune-mediated diseases, including psoriasis, lupus, spondyloarthritides, and Crohn’s disease.
BMS-986165 is a potent, highly-selective, oral, small molecule inhibitor of TYK2. A 
comprehensive in vitro and in vivo characterization of BMS-986165 has been established and 
supports the development of this compound in humans. Inhibition of TYK2 is expected to provide 
therapeutic benefit for subjects with psoriasis for multiple reasons: 1) Many of the pathways in the 
TYK2 signaling cascade (IL-23 and the downstream mediators IL-17 and IL-22; IFNα) have been 
implicated in pathogenesis of psoriasis.8 2) Biologic agents targeting the IL-17, IL-23p19, and IL-
12/23 p40 pathways have been approved for and are highly efficacious in the treatment of psoriasis. 
 
 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
35
 
2.2.1 
Early Clinical Development 
The clinical data available to date supporting the safety, pharmacokinetics (PK), and 
pharmacodynamics (PD) of BMS-986165 are from 5 completed Phase 1 studies in healthy subjects 
(IM011002, IM011015, IM011016, IM011031, and IM011039) and 1 completed Phase 2 study in 
adult subjects with moderate-to-severe plaque psoriasis (IM011011).  
Overall, BMS-986165 has been generally well-tolerated across all studies, and no safety issues 
have been identified to limit the investigation of the dose of BMS-986165 up to 12 mg QD in 
further clinical studies. A detailed description of the chemistry, pharmacology, efficacy, and safety 
of BMS-986165 is provided in the Investigator Brochure (IB). 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
36
3 
OBJECTIVES AND ENDPOINTS 
Table 4:
Objectives and Endpoints
Objective
Endpoint
Primary
x
Assess whether BMS-986165 is superior to placebo at 
Week 
16 
in 
the 
treatment 
of 
subjects 
with 
moderate-to-severe plaque psoriasis
x
static Physician Global Assessment (sPGA) 
0/1 response
x
Psoriasis Area and Severity Index (PASI) 75
response (defined as a 75% improvement in 
PASI score from baseline)
Secondary 
x
Assess whether BMS-986165 is superior to apremilast at 
Week 16
x
sPGA 0/1 response
x
PASI 75 response
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
x
Assess whether BMS-986165 is superior to apremilast at 
Week 52
x
sPGA 0/1 response
x
PASI 75 response
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
x
Assess whether BMS-986165 is superior to placebo over 
the first 16 weeks of treatment
x
sPGA 0/1 response
x
PASI 75 response
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
x
Assess whether BMS-986165 is superior to apremilast 
over 52 weeks of treatment
x
sPGA 0/1 response
x
PASI 75 response
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
37
Table 4:
Objectives and Endpoints
Objective
Endpoint
x
PASI 90 response
x
sPGA 0 response
x
PASI 100 response
x
Assess whether BMS-986165 is superior to placebo in 
scalp psoriasis through Week 16 in those subjects who 
have baseline scalp severity Physician’s Global
Assessment (ss-PGA) score ≥3
x
ss-PGA 0/1 response 
x
Assess whether BMS-986165 is superior to placebo in 
nail psoriasis through Week 16 in those subjects who 
have baseline Physician’s Global Assessment-Fingernail 
(PGA-F) psoriasis score ≥3
x
PGA-F 0/1 response
x
Assess whether BMS-986165 is superior to placebo in 
palmoplantar psoriasis through Week 16 in those 
subjects who have baseline palmoplantar Physician’s 
Global Assessment (pp-PGA) score ≥3
x
pp-PGA 0/1 response
x
Evaluate improvement in patient-reported outcomes for 
BMS-986165 compared with placebo through Week 16
x
Evaluate improvement in patient-reported outcomes for 
BMS-986165 compared with apremilast through 
Week 52
x
Change from baseline in Psoriasis Symptoms 
and Signs Diary (PSSD) symptom score, sign 
score, and total score
x
Change from baseline in Dermatology Life 
Quality Index (DLQI) score
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
38
Table 4:
Objectives and Endpoints
Objective
Endpoint
x
DLQI 0/1 (among subjects with a baseline 
DLQI score ≥2)
4 
STUDY DESIGN 
4.1 
Overall Design 
This will be a 52-week, multi-center, randomized, double-blind, double-dummy, placebo- and 
active comparator-controlled study to evaluate the safety and efficacy of BMS-986165 vs placebo 
and apremilast. A total of 600 qualified subjects with moderate-to-severe plaque psoriasis will be 
enrolled. 
The duration of study participation is approximately 60 weeks and will be divided into the 
following periods: screening (up to 4 weeks), treatment (52 weeks), and follow-up (4 weeks). 
Physical exams, 12-lead ECGs, clinical laboratory evaluations, and other assessments will be done 
at select visits during the study. Subjects in this study will be monitored for AEs. 
 
 
4.1.1 
Screening Period 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
39
Subjects will be evaluated during the screening period to ensure they meet eligibility criteria. A 
detailed medical history will be done at this time, as well as a complete physical exam. Psoriasis-
related history, which will include length of diagnosis, body involvement, and history of systemic 
treatment, will be assessed here. Depression and suicidality assessments will also be performed. 
An evaluation for tuberculosis will be done based on medical history, recent chest imaging, and a 
QuantiFERON-TB Gold test. 
4.1.2 
Treatment Period 
Qualified subjects who have completed the screening procedures and have met the 
inclusion/exclusion criteria will be randomized on Day 1 in a 2:1:1 ratio, respectively to one of the 
following 3 treatment groups: 
x
BMS-986165 6 mg QD 
x
Placebo 
x
Apremilast titrated to 30 mg BID as follows: 
o
Day 1: 10 mg tablet in the morning 
o
Day 2: 10 mg tablet in the morning and evening 
o
Day 3: 10 mg tablet in the morning and 20 mg tablet in the evening 
o
Day 4: 20 mg tablet in the morning and the evening 
o
Day 5: 20 mg tablet in the morning and 30 mg tablet in the evening 
o
Day 6 and thereafter: 30 mg tablet in the morning and the evening 
Dummy tablets (placebo to the BMS-985165 6 mg tablet, placebo to apremilast 30 mg tablet BID, 
and placebo to apremilast 10 mg, 20 mg, and 30 mg during titration) will be administered to the 
subjects to maintain blinding. Additional details are provided in Section 6.1. Note that apremilast 
will not be used as a treatment arm in China. 
Randomization should not occur until at least 8 days after the Screening Visit to allow collection 
of PSSD data during screening in order to calculate a baseline PSSD score. Randomization will be 
stratified by geographic region (U.S., Japan [body weight stratum will not be applied in Japan], 
China [body weight stratum will not be applied in China], and Rest of World), previous biologic 
use (for psoriasis, psoriatic arthritis or other inflammatory diseases only; yes/no), and body weight 
(≥90 kg and <90 kg). If subjects from China are not enrolled in the study, then the stratification 
level for China will not be utilized. As this is designed to be a global study across multiple 
countries, randomization in each country will be targeted to approximately 35% or less of the total 
sample size. This change is being implemented to achieve geographical representation across 
countries and to minimize the potential for any single country to have a disproportionate impact 
on the overall efficacy and/or safety profile. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
40
4.1.3 
Week 16 
The coprimary endpoints (sPGA 0/1 and PASI 75) will be assessed at Week 16. Subjects receiving 
placebo will be switched in a blinded manner to BMS-986165 6 mg QD at Week 16. Subjects who 
are randomized to BMS-986165 6 mg QD or apremilast 30 mg BID will continue their treatment 
regimen. 
4.1.4 
Week 24 
At Week 24, subjects originally randomized to apremilast 30 mg BID who do not achieve PASI 50 
response will be switched in a blinded manner to BMS-986165 6 mg QD. Subjects in the 
apremilast treatment arm who achieve PASI 50 response at Week 24 will continue to receive 
apremilast 30 mg BID in a blinded manner through Week 52.
During the Week 24 assessment, a subject who has an sPGA ≥3 
 may be treated with 
restricted topicals/shampoos as described in Section 6.7.1 at the investigator’s discretion. These 
treatments may be only initiated at Week 24, and not at subsequent time points. A subject who is 
initiated on these treatments at Week 24 may use them as needed per the investigator’s judgment 
through Week 52. 
4.1.5 
Week 52 and Follow-up Period 
The follow-up period is a 4-week window after the Week 52 visit, unless the subject rolls over into 
the long-term extension. The subject will be encouraged to report any SAEs or AEs experienced 
during this time. 
Subjects who discontinue study treatment early should remain in the study for protocol-specified 
procedures (please refer to Section 7.1 for more details).
Subjects completing 52 weeks of treatment will be offered the opportunity to roll over to a separate 
long-term extension study (≥2 years) where they will be treated with BMS-986165 6 mg QD. 
The study design schematic is presented in Figure 1.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
41
Figure 1: 
Study Design Schematic 
*Apremilast is titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing as described in Section 4.1.2
Abbreviations: BID = twice daily; QD = once daily; R = randomize 
The coprimary endpoints will be evaluated at Week 16.
4.1.6 
Data Monitoring Committee and Other External Committees 
4.1.6.1 
Data Monitoring Committee 
An external data monitoring committee (DMC) with multi-disciplinary representation will be 
established to evaluate on a periodic basis; AEs, laboratory measurements, and safety assessments 
to ensure the ongoing safety of study subjects. An independent reporting statistician not involved 
in the conduct of the study will be designated by 
 to provide the DMC with essential safety 
data during the study. 
The DMC responsibilities, authorities, and procedures will be documented and followed according 
to the DMC charter. 
4.1.6.2 
Infection Adjudication Committee 
An independent Infection Adjudication Committee, composed of individuals with relevant 
expertise, will blindly review and adjudicate infection AEs, such as opportunistic infections, 
influenza, herpes zoster, and TB, reported in the study per criteria specified in a separate charter.
Additional information about these infections may be collected on the case report form in order to 
characterize and understand them. The Adjudication Committee members will be blinded to the 
treatment assignment of subjects. The structure, responsibilities, and procedures of the 
Adjudication Committee will be outlined in a charter. The Adjudication Committee is distinct from 
the DMC and Adjudication Committee members will not be investigators on the study. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
42
4.1.6.3 
CV Adjudication Committee 
An independent cardiovascular (CV) Adjudication Committee, composed of individuals with 
relevant expertise, will blindly review and adjudicate cardiovascular and cerebrovascular AEs such 
as, but not limited to, Major Adverse Cardiovascular Events (MACE) that include death, non-fatal 
myocardial infarction, non-fatal stroke; revascularization procedures; heart failure; dysrhythmias; 
heart blocks; and thrombotic events reported in the study per criteria specified in a separate charter.
Additional information about cardiovascular and cerebrovascular AEs may be collected on the 
case report form in order to characterize and understand them. The Adjudication Committee 
members will be blinded to the treatment assignment of subjects. The structure, responsibilities, 
and procedures of the Adjudication Committee will be outlined in a charter. The Adjudication 
Committee is distinct from the DMC and Adjudication Committee members will not be 
investigators on the study. 
4.1.6.4 
Suicidal Ideation and Behavior Adjudication Committee 
An independent Suicidal Ideation and Behavior Adjudication Committee, composed of individuals 
with relevant expertise, will blindly review and adjudicate suicidal ideation/behavior reported in 
the study per criteria specified in a separate charter. Additional information about suicidal 
ideation/behavior may be collected on the case report form. The Adjudication Committee members 
will be blinded to the treatment assignment of subjects. The structure, responsibilities, and 
procedures of the Adjudication Committee will be outlined in a charter. The Adjudication 
Committee is distinct from the DMC and Adjudication Committee members will not be 
investigators on the study. 
4.2 
Number of Subjects 
Approximately 600 qualified subjects will be randomized in a 2:1:1 ratio to BMS-986165 
6 mg QD, apremilast 30 mg BID, and placebo, respectively. 
 
  
4.3 
End of Study Definition 
The duration of study participation for individual subjects is expected to be up to 60 weeks (420 
days), which includes screening (up to 4 weeks), treatment (52 weeks) and follow-up (up to 4 
weeks) periods. 
The start of the study is defined as first visit for first subject screened. The end of the study is 
defined as the last visit or scheduled procedure shown in the Schedule of Activities (Section 1.3)
for the last subject. Study completion is defined as the final date on which data was or is expected 
to be collected (Week 56 for collection of potential SAEs). 
4.4 
Scientific Rationale for Study Design 
This Phase 3 study will be conducted in a population of subjects with stable moderate-to-severe 
plaque psoriasis who are candidates for systemic psoriasis therapy. The study is designed to 
confirm the efficacy and safety of BMS-986165 compared with placebo and apremilast in 
achieving sPGA of 0/1 and PASI 75 at Week 16. The sPGA and PASI 75 are standard measures 
in clinical trials of demonstrating efficacy of systemic psoriasis treatments. A placebo arm is 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
43
included in this study for a short duration of 16 weeks to provide a control for the natural 
fluctuation of psoriasis activity that may occur and to provide a safety standard for comparison. 
Subjects in the placebo arm will be switched to BMS-986165 at Week 16 to provide them psoriasis 
treatment after the endpoints are collected. Apremilast is included as the active control in this study 
as it is an approved, widely used, oral, daily medication for psoriasis. Week 16 was chosen as it 
would allow enough time for BMS-986165 as well as apremilast to treat psoriasis. In addition, 
prior apremilast registrational trials had reported psoriasis-related outcomes at Week 16 as their 
primary endpoints. Subjects in the apremilast arm who do not achieve PASI 50 at Week 24 will 
be switched in a blinded fashion to BMS-986165. This will allow subjects who are not responding 
to apremilast to receive an alternate study treatment. PASI 50 is used to justify the switch because 
achieving PASI 50 has been shown to have a meaningful impact on quality of life in people with 
psoriasis.24
5 
STUDY POPULATION 
Eligibility criteria for this study have been carefully considered to ensure: 1) selection of 
appropriate subjects with psoriasis, 2) safety of the study subjects and 3) the results of the study 
can be used for regulatory filing and other purposes. It is imperative that subjects fully meet all 
eligibility criteria. 
All screening and randomization evaluations must be completed and reviewed to confirm that 
potential subjects meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for screening 
failure, as applicable. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
44
5.1 
Inclusion Criteria 
In order to be eligible to participate in this study, an individual must meet all of the following 
criteria: 
1) Signed Written Informed Consent 
a) Subjects must be willing to participate in the study and sign the informed consent form 
(ICF) 
2) Type of Subject and Target Disease Characteristics 
a) Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable 
psoriasis is defined as no morphology changes or significant flares of disease activity in 
the opinion of the investigator 
b) Deemed by the investigator to be a candidate for phototherapy or systemic therapy 
c) ≥10% of BSA involvement at Screening Visit and Day 1
d) Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician’s Global 
Assessment (sPGA) ≥3 at Screening Visit and Day 1
3) Age and Reproductive Status 
a) Men and women aged ≥18 years at the time of Screening Visit 
b) Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at 
Screening Visit, and a negative urine pregnancy test (minimum sensitivity 25 IU/L or 
equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start 
of study drug 
c) Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the 
study period 
d) Women of childbearing potential must agree to use correctly a highly effective method(s) 
of contraception for the duration of treatment (52 weeks) with study drug(s) BMS-986165 
plus 5 half-lives of study drug (3 days) plus 30 days (duration of ovulatory cycle) for a total 
of 33 days post-treatment completion (total of 33 days after last dose of study drug). 
WOCBP who are continuously not heterosexually active are exempt from contraceptive 
requirements, but must still undergo pregnancy testing as described in this protocol 
e) Male subjects who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception (APPENDIX 4) for the duration of treatment with study 
treatment(s) plus 5 half-lives of the study treatment (3 days) for a total of 3 days
post-treatment completion. In addition, male subjects must be willing to refrain from sperm 
donation during this time 
Investigators shall counsel WOCBP, and male subjects who are sexually active with WOCBP, on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on the use of highly effective methods of contraception, (APPENDIX 4)
which, have a failure rate of <1% when used consistently and correctly. 
5.2 
Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from participation in this 
study: 
1) Target Disease Exceptions 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
45
a) Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced 
psoriasis) at Screening or Day 1 
2) Infectious/Immune-related Exclusions 
a) History or evidence of outpatient active infection and/or febrile illness within 7 days prior 
to Day 1  
b) History of serious bacterial, fungal, or viral infection requiring hospitalization and 
intravenous (IV) antimicrobial treatment within 60 days prior to Day 1 
c) Any untreated bacterial infection within 60 days prior to Day 1 
d) Any ongoing evidence of chronic, bacterial infection (eg chronic pyelonephritis, chronic 
osteomyelitis, chronic bronchiectasis) 
e) Any history of proven infection of a joint prosthesis in which the prosthesis was not 
removed or replaced, or received antibiotics for suspected infection of a joint prosthesis in 
which the prosthesis was not removed or replaced 
f)
Received live vaccines within 60 days prior to Day 1, or plans to receive a live vaccine 
during the study, or within 60 days after completing study treatment 
g) Presence of herpes zoster lesions at Screening or Day 1 
h) History of serious herpes zoster or serious herpes simplex infection which includes, but is 
not limited to, any episode of disseminated herpes simplex, multidermatomal herpes zoster, 
herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (recurrent is defined as 
2 episodes within 2 years) 
i)
Evidence of, or test positive for, hepatitis B virus (HBV) at Screening. Positive hepatitis B 
lab testing is defined as: 1) Positive hepatitis B surface antigen (HBsAg+) OR 2) Presence 
of hepatitis B virus deoxyribonucleic acid (DNA) OR 3) Positive anti-hepatitis B core 
antibody without concurrent positive hepatitis B surface antibody (HBcAb+ and HBsAb-)
j)
Evidence of, or test positive for, hepatitis C virus (HCV) at Screening. A positive test for 
HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab) AND 2) positive 
via a confirmatory test for HCV (eg, HCV polymerase chain reaction) 
k) Positive for human immunodeficiency virus by antibody testing (HIV-1 and -2 Ab) at 
Screening 
l)
Any history of known or suspected congenital or acquired immunodeficiency state or 
condition that would compromise the subject’s immune status (eg, history of opportunistic
infections [eg, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidioidomycosis], 
history of splenectomy, primary immunodeficiency) 
3) Any of the following TB criteria:
a) History of active TB prior to Screening Visit, regardless of completion of adequate 
treatment 
b) Signs or symptoms of active TB (eg, fever, cough, night sweats, and weight loss) during 
screening as judged by the investigator 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
46
c) Any imaging of the chest (eg, chest x-ray, chest computed tomography [CT] scan) obtained 
during the screening period or anytime within 6 months prior to Screening with 
documentation, showing evidence of current active or history of active pulmonary TB 
d) Latent TB infection (LTBI) defined as positive IFN gamma release assay (IGRA), by 
QuantiFERON-TB Gold testing at Screening, in the absence of clinical manifestations 
Note: Subject is eligible if (i) there are no current signs or symptoms of active TB AND
(ii) subject has received adequate documented treatment for LTBI within 5 years of 
Screening OR has initiated prophylactic treatment for LTBI per local guidelines and is 
rescreened after 1 month of treatment. To continue in the study, subject must agree to 
complete a locally-recommended course of treatment for LTBI. Use of rifampin, however, 
is not recommended as it can reduce efficacy of apremilast used as a comparator in this 
trial. 
Note: An IGRA test that is indeterminate with no signs or symptoms of active TB must be 
retested for confirmation. If the second test is again indeterminate, the subject will be 
excluded from the study. If the retest is positive, the subject should be treated as having 
LTBI. If the retest is negative, subject may be eligible provided no other exclusion criteria 
for TB are met. 
4) Medical History and Concurrent Diseases 
a) Any major surgery within 8 weeks prior to Day 1, or any planned surgery for the first 52 
weeks of the study 
b) Has donated blood >500 mL within 4 weeks prior to Day 1, or plans to donate blood during 
the course of the study 
c) Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1 
d) Medical marijuana or prescription marijuana taken for medicinal reasons 
e) Any major illness/condition or evidence of an unstable clinical condition (eg, renal, 
hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, 
immunologic, or local active infection/infectious illness) that, in the investigator’s 
judgment or after consultation with the Medical Monitor, will substantially increase the 
risk to the subject if he or she participates in the study 
f)
Unstable cardiovascular disease, defined as a recent clinical cardiovascular event (eg, 
unstable angina, myocardial infarction, stroke, rapid atrial fibrillation) in the last 3 months 
prior to Screening, or a cardiac hospitalization (eg, revascularization procedure, pacemaker 
implantation) within 3 months prior to Screening 
g) Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) 
>160 mm Hg or diastolic BP >100 mm Hg  
Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this 
limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If 
the repeat value is less than the criterion limits, the second value may be accepted 
h) Class III or IV congestive heart failure by New York Heart Association Criteria 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
47
i)
Has cancer or history of cancer (solid organ or hematologic including myelodysplastic 
syndrome) or lymphoproliferative disease within the previous 5 years (other than resected 
cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has 
been treated with no evidence of recurrence) 
j)
Any significant/uncontrolled neuropsychiatric illness judged as clinically significant by the 
investigator during Screening or at Day 1 
OR
Any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by medical 
history or by electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) 
documentation, or by answering “yes” to Question 4 or 5 for suicidal ideation on the 
eC-SSRS at Screening or at Day 1, or is clinically deemed to have a suicide risk by the 
investigator 
k) Prior exposure to investigational product (ie, BMS-986165 or apremilast) 
l)
If the subject has received biologics previously, the following exclusion criteria for 
washout will apply:  
i)
Antibodies to IL-12, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, 
ixekizumab, or guselkumab) within 6 months of Day 1 
ii) TNF inhibitor(s) (eg, etanercept, adalimumab, infliximab, certolizumab) within 2 
months of Day 1 
iii) Agents that modulate integrin pathways to impact lymphocyte trafficking (eg 
natalizumab), or agents that modulate B cells or T cells (eg, alemtuzumab, abatacept, 
or visilizumab) within 3 months of Day 1 
iv) Rituximab within 6 months of Day 1 
m) Has received systemic nonbiologic psoriasis medications and/or any systemic 
immunosuppressants (including, but not limited to, methotrexate, azathioprine, 
cyclosporine, JAK inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, 
hydroxyurea, tacrolimus, oral or injectable corticosteroids, retinoids, 1,25-dihydroxy 
vitamin D3 and analogues, psoralens, sulfasalazine, or fumaric acid derivatives) within 4 
weeks prior to Day 1 
n) Has used leflunomide within 6 months prior to Day 1 
o) Has used opioid analgesics within 4 weeks prior to Day 1 
p) Has received lithium, antimalarials, or intramuscular (IM) gold within 4 weeks of the first 
administration of any study medication 
q) Has used any strong CYP450 inducers (eg, rifampin, phenobarbital, carbamazepine, 
phenytoin) within 4 weeks prior to Day 1 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
48
r)
Has received phototherapy (including either oral and topical PUVA light therapy, 
ultraviolet B [UVB] or self-treatment with tanning beds or therapeutic sunbathing) within 
4 weeks prior to Day 1 
s) Has used topical medications/treatments that could affect psoriasis evaluation (including, 
but not limited to, high potency corticosteroids [WHO Classes I-V], >3% salicylic acid, 
urea, alpha- or beta-hydroxy acids, anthralin, calcipotriene, topical vitamin D derivatives, 
retinoids, tazarotene, methoxsalen, trimethylpsoralens, pimecrolimus, and tacrolimus) 
within 2 weeks prior to Day 1 
Note: Low potency topical steroids (WHO Class VI and VII) are permitted on the palms, 
soles, face, and intertriginous areas but should not be used within 24 hours prior to any 
study visit. Bland emollients (defined as emollients without urea or alpha or  
beta-hydroxy acids or other ingredients which are pharmaceutically active) are allowed on 
all body regions but should not be used within 24 hours prior to any study visit. 
t)
Use of shampoos that contain corticosteroids, coal tar, >3% salicylic acid, or vitamin D3 
analogues within 2 weeks prior to Day 1 
u) Has received an experimental antibody or experimental biologic therapy within the 
previous 6 months, OR received any other experimental therapy or new investigational 
agent within 30 days or 5 half-lives (whichever is longer) prior to Day 1 OR is currently 
enrolled in an investigational study 
v) Any other sound medical, psychiatric and/or social reason as determined by the investigator 
5) Physical and Laboratory Evaluations 
a) At Screening 
i)
Absolute WBC count <3000/mm3  
ii)
Absolute lymphocyte count <500/mm3  
iii)
Absolute neutrophil count <1000/mm3  
iv)
Platelet count <100,000/mm3  
v)
Hemoglobin <9 g/dL  
vi)
ALT and/or AST >3 × upper limit of normal (ULN) 
vii)
Total unconjugated and/or conjugated bilirubin >2 × ULN 
viii) Thyroid-stimulating hormone (TSH) outside the normal reference range 
AND
Free T4 (thyroxine) or T3 (triiodothyronine) outside the normal reference range 
b) ECG abnormalities that are considered clinically significant and would pose an 
unacceptable risk to the subject if participating in the study 
c) Renal impairment based on an estimated glomerular filtration rate (eGFR) <45 mL/min 
d) Inability to be venipunctured and/or tolerate venous access 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
49
e) Any other significant laboratory abnormalities that, in the opinion of the investigator, might 
place the subject at unacceptable risk for participation in this study 
6) Allergies and Adverse Drug Reactions 
a) History of any significant drug allergy (such as anaphylaxis) 
7) Other Exclusion Criteria 
a) Prisoners or subjects who are involuntarily incarcerated. (Note: Under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a subject. Strict conditions apply, and BMS approval is required). 
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness 
c) Inability to comply with restrictions and prohibited activities/treatments as listed in the 
study protocol 
d) Site personnel or their immediate family 
e) Any contraindications listed in the country-specific label for apremilast 
5.3 
Lifestyle Restrictions 
General skin care measures (with above restrictions for topical treatments) that are standard for 
patients with plaque psoriasis are permitted. Subjects should avoid excessive sun exposure and 
avoid risks that are known to provoke flare of psoriasis. 
5.3.1 
Meals and Dietary Restrictions 
Study treatment may be taken without regard to meals, however, subjects are required to fast for a 
minimum of 10 hours before visits on which fasting lipid, fasting glucose
 
samples will be drawn. 
5.3.2 
Caffeine, Alcohol and Tobacco 
No restrictions are required; however, extensive use of caffeine, alcohol and tobacco should be 
avoided. 
5.3.3 
Activity 
No restrictions are required; however, unusual physical exertion should be avoided during the 
study. 
5.4 
Screen Failures 
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently randomized in the study for any reason. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure subjects, to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries 
from regulatory authorities. Minimal set of screen failure information includes date of consent, 
demography, screen failure details (ie, eligibility criteria that the subject did not meet), and any 
serious AEs during the screening period. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
50
5.4.1 
Retesting During Screening or Rescreening 
For laboratory parameters that initially do not meet eligibility requirements, a single retest within 
the 28-day screening period is permitted before subject is declared a screen failure. This is an effort 
to find all possible well-qualified subjects. Consultation with the Medical Monitor may be needed 
to identify whether repeat testing of any particular parameter would be clinically relevant. 
The study permits the rescreening (after the end of the initial 28-day screening period) of a subject 
who discontinues the study as a pretreatment failure (ie, the subject fails to meet eligibility criteria 
and has not been treated). The subject must be reconsented, will be assigned a new identification 
number, and a full Screening Visit must be performed again. A subject can only be rescreened 1 
time (ie, if the subject fails 1 rescreening attempt, no additional rescreening is allowed). Depending 
on the timing of rescreening, repeat chest imaging may not be required. Duration of existing 
treatments and required discontinuation periods shall be considered relative to the new Screening 
Visit and/or randomization. 
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the subject’s most current clinical state.
6 
TREATMENT 
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or 
medical device intended to be administered to a study subject according to the study randomization 
or treatment allocation. 
Study 
treatment 
includes 
both 
Investigational 
[Medicinal] 
Product 
(IP/IMP) 
and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following: 
BMS-986165, placebo, and apremilast. 
An IP, also known as IMP in some regions, is defined as a pharmaceutical form of an active 
substance or placebo being tested or used as a reference in a clinical study, including products 
already with a marketing authorization but used or assembled (formulated or packaged) differently 
than the authorized form, or used for an unauthorized indication, or when used to gain further 
information about the authorized form. 
Other medications used as support or escape medication for preventive, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as  
non-IP. Table 5 shows the study treatments for Protocol IM011046. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
51
Table 5:
Study Treatments for IM011046
Product 
Description/Class and 
Dosage Form
Potency
IP/Non-IMP
Blinded or 
Open-Label
Packaging / 
Appearance
Storage Conditions
(per label)
BMS-986165 tablet
6 mg
IP
Blinded
Bottle
Store at 15 to 25°C; Store in 
a tightly closed container; 
Protect from light
Placebo tablet to match 
BMS-986165 6 mg
n/a
IP
Blinded
Bottle
Store at 15 to 25°C; Store in 
a tightly closed container; 
Protect from light
Apremilast tablet
10 mg*
IP
Blinded
Blister card
Store tablets below 30°C 
(86°F). Store in original 
container
Placebo tablet to match 
apremilast 10 mg
n/a
IP
Blinded
Blister card
Store tablets below 30°C 
(86°F). Store in original 
container
Apremilast tablet
20 mg†
IP
Blinded
Blister card
Store tablets below 30°C 
(86°F). Store in original 
container
Placebo tablet to match 
apremilast 20 mg
n/a
IP
Blinded
Blister card
Store tablets below 30°C 
(86°F). Store in original 
container
Apremilast tablet
30 mg‡
IP
Blinded
Bottle
Store tablets below 30°C 
(86°F). Store in original 
container
Placebo tablet to match 
apremilast 30 mg
n/a
IP
Blinded
Bottle
Store tablets below 30°C 
(86°F). Store in original 
container
IP = investigational product; IMP = investigational medical product; n/a = not applicable 
*Used for titration Day 1 through Day 3 morning dose 
†Used for titration Day 3 evening dose through Day 5 morning dose
‡From Day 5 evening dose onwards.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
52
6.1 
Treatments Administered 
Study treatment will be administered in a double-blind, double-dummy fashion as described in 
Section 4.1.2. The selection and timing of dose for each subject is as follows: 
Table 6:
Selection and Timing of Dose
Study Treatment
Unit dose 
strength(s)/Dosage 
level(s)
Dosage formulation
Frequency of Administration
Route of 
Administration
6 mg QD 
BMS-986165
6 mg
1 active tablet QD in the morning; 1 
placebo titration kit* then 2 apremilast 
placebo (1 tablet in the morning, 1 tablet 
in the evening)
oral
30 mg BID 
apremilast
30 mg
1 active titration kit* then 1 active 
morning and evening and 1 BMS-986165
placebo once daily in the morning
oral
Placebo BID 
n/a
1 placebo apremilast titration kit* then 2 
apremilast placebo (1 tablet in the 
morning, 1 tablet in the evening) and 1 
BMS-986165 placebo once daily in the 
morning
oral
Abbreviations: BID = twice daily; n/a = not applicable; QD = once daily 
*Titration kit is described in Section 6.1.1
6.1.1 
Titration Kit for Active and Placebo Apremilast 
Apremilast will be titrated over 5 days to a maintenance dose of 30 mg BID. To maintain the blind 
between subjects receiving apremilast and BMS-986165 during the titration period, active 
apremilast and matching apremilast placebo tablets will be provided. This will be supplied in an 
18-day titration kit as follows: 
One 10 mg tablet in the morning on Day 1; two 10 mg tablets (one in the morning, one in the 
evening) on Day 2; one 10 mg tablet in the morning and one 20 mg tablet in the evening on Day 3; 
two 20 mg tablets (one tablet in the morning, one tablet in the evening) on Day 4; one 20 mg tablet 
in the morning and one 30 mg tablet in the evening on Day 5; one 30 mg tablet in the morning and 
one 30 mg tablet in the evening for each Day 6 through Day 18. 
6.2 
Method of Treatment Assignment 
Before the study is initiated, each user (at investigative sites) will receive log-in information and 
directions on how to access the interactive response technology (IRT) system. At the time of the 
Screening Visit, immediately after informed consent is obtained and before any study-related 
procedures are performed, the investigative site will access the enrollment option of the IRT 
system for assignment of a subject number for all subjects, including subjects not subsequently 
randomized or treated. The subject number is assigned sequentially by the system and will be 
unique across all sites. All enrolled subjects will be assigned sequential subject numbers. The 
subject number will not be used for any other subject. If a subject is rescreened, they will be given 
a new identification number. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
53
At Week 0 (Day 1), subjects who meet all criteria for enrollment at Screening and Day 1 will be 
centrally randomized in a 2:1:1 ratio to BMS-986165 6 mg QD, placebo, or apremilast 30 mg BID 
as determined by a computer-generated randomization schedule using IRT. The randomization 
lists will be generated by the IRT vendor using a permuted block design within each combination 
of stratum level. The randomization in this study will be stratified by geographic region (U.S., 
Japan [body weight stratum will not be applied in Japan], China [body weight stratum will not be 
applied in China], and Rest of World), previous biologic use (for psoriasis, psoriatic arthritis or 
other inflammatory diseases only; yes/no), and body weight (≥90 kg and <90 kg). As this is 
designed to be a global study across multiple countries, randomization in each country will be 
targeted to approximately 35% or less of the total sample size. This change is being implemented 
to achieve geographical representation across countries and to minimize the potential for any single 
country to have a disproportionate impact on the overall efficacy and/or safety profile.
After all inclusion/exclusion criteria have been met for a subject, the investigative site will access 
the IRT on Day 1 for the purposes of randomizing a subject. A treatment group will be assigned 
by IRT based on the above-described randomization schedule and each subject will be assigned a 
unique randomization number. In addition, a unique kit number will be assigned to the subject 
corresponding to the treatment assignment. 
A kit will contain adequate study treatment for a 4-week supply. At subsequent visits, when new 
treatment kits need to be provided, the investigative site will access the IRT to obtain the kit 
number to assign to the subject. Study treatment will be dispensed at study visits as shown in the 
Schedule of Activities (Section 1.3).
At Week 16, subjects receiving placebo will be switched in a blinded manner to BMS-986165 
6 mg QD. 
At Week 24, subjects originally randomized to apremilast 30 mg BID who do not achieve PASI 50 
response will be switched in a blinded manner to BMS-986165 6 mg QD. Subjects originally 
randomized to apremilast 30 mg BID who achieve PASI 50 response at Week 24 will continue to 
receive apremilast 30 mg BID in a blinded manner. The investigative site and other study personnel 
will not have knowledge of the PASI 50 score at this visit and will therefore remain blinded. 
6.3 
Blinding
6.3.1 
Maintaining the Blind 
Blinded treatment assignments will be managed using IRT. Throughout the study, subjects will 
receive matching placebo (for BMS-986165 and/or apremilast) as needed to maintain the treatment 
blind. IP supply will be controlled by IRT at each visit. 
All tablets are identical in appearance and will be supplied in blister cards or bottles with each 
daily dose made up of the appropriate combination of active and/or placebo tablets to provide the 
correct treatment, as shown in Table 5. Investigative site staff, Sponsor and designee personnel, 
and subjects and their families will remain blinded to treatment assignments. 
 
 
 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
54
 
 
6.3.2 
Circumstances for Unblinding 
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subject in which knowledge of the IP 
is critical to the subject's management, the blind for that subject may be broken by the investigator. 
The subject’s safety takes priority over any other considerations in determining if a treatment 
assignment should be unblinded. 
Before breaking the blind of an individual subject's treatment, the investigator should determine 
that the unblinded information is necessary, ie, that it will alter the subject's immediate 
management. In many cases, particularly when the emergency is clearly not related to the IP, the 
problem may be properly managed by assuming that the subject is receiving active product. It is 
highly desirable that the decision to unblind treatment assignment be discussed with the Medical 
Monitor, but the investigator always has ultimate authority for the decision to unblind. The 
principal investigator should only call in for emergency unblinding AFTER the decision to 
discontinue the subject has been made. 
In case of an emergency, the investigator has unrestricted access to randomization information via 
IRT and is capable of breaking the blind through the IRT system without prior approval from the 
Sponsor. After the unblinding, the investigator shall notify the Medical Monitor and/or study 
director. The method of unblinding for emergency purposes is described in the IRT manual. 
Subject and unblinded treatment information and the reason for the blind being broken must be 
recorded on the appropriate study status page of the electronic case report form (eCRF). After 
unblinding via IRT, the investigator shall notify the Medical Monitor. 
In cases of accidental unblinding, contact the Medical Monitor and ensure every attempt is made 
to preserve the blind. Any request to unblind a subject for nonemergency purposes must be 
discussed with the Medical Monitor prior to unblinding. 
If a subject is unblinded for any reason, the subject will be discontinued from treatment. 
6.4 
Dosage Modification 
There is no provision for dose-modification of study treatment. If a subject interrupts treatment 
due to an AE, study treatment can be restarted in consultation with the Medical Monitor. 
6.5 
Preparation/Handling/Storage/Accountability 
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the investigator to ensure that the IP is only dispensed to study subjects. The IP must be dispensed 
only from official study sites by authorized personnel according to local regulations. 
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment 
should not be dispensed and BMS should be contacted immediately. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
55
Study treatment not supplied by BMS will be stored in accordance with the package insert. 
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets). 
Guidance and information for final disposition of unused study treatment are provided in 
APPENDIX 2. 
6.5.1 
Retained Samples for Bioavailability/Bioequivalence 
Not applicable. 
6.6 
Treatment Compliance 
Study treatment compliance will be periodically monitored using standard drug accountability 
procedures (comparing the number of tablets returned to number dispensed, considering the 
expected regimen and any reported missed doses). Drug accountability will be reviewed by the 
investigative site staff at each visit to confirm treatment compliance. Site staff will discuss any 
discrepancies with the subject and remind the subject of the importance of compliance with the 
assigned regimen. A real-time monitoring platform may be used. 
6.7 
Concomitant Therapy 
6.7.1 
Prohibited and/or Restricted Treatments 
Prohibited and/or restricted medications during the study are described below. Medications taken 
within 4 weeks prior to study drug administration must be recorded on the CRF. 
1) Exposure to any investigational drug or placebo outside of the current study 
2) Any concurrent use of  strong CYP450 inducers according to the US package insert for 
apremilast as it may reduce apremilast efficacy. Examples include rifampin, phenobarbital, 
carbamazepine, and phenytoin, unless it is considered necessary for the subject’s welfare 
and/or treatment of an AE/SAE 
3) Use of any medications/therapy that would aggravate psoriasis. These include agents such as 
lithium, antimalarials (quinacrine, chloroquine, and hydroxychloroquine), propranolol, 
indomethacin, and quinidine unless it is considered necessary for the subject’s welfare and/or 
treatment of an AE/SAE 
4) Use of opioid analgesics unless it is considered necessary for the subject’s welfare and/or 
treatment of an AE/SAE 
5) Phototherapy; use of tanning booths or therapeutic sunbathing  
6) Any use of biologic medications (eg, adalimumab, etanercept, infliximab, ustekinumab) 
7) Any use of oral psoriasis medications (eg, methotrexate, cyclosporine, retinoids, fumaric acid 
derivatives) for any indication 
8) Any use of oral or injectable corticosteroids (prednisone, methylprednisolone, etc.), unless it 
is considered necessary for the subject’s welfare and/or treatment of an AE/SAE
Note: otic, ophthalmic, nasal, or inhaled corticosteroids within recommended doses and with 
no systemic effects are permitted 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
56
9) Any topical medications/treatments, which are used for any indication, that could affect 
psoriasis evaluation (including, but not limited to, high potency corticosteroids [WHO Classes 
I-V], >3% salicyclic acid, urea, alpha- or beta-hydroxy acids, anthralin, calcipotriene, 
vitamin D derivatives, retinoids, tazarotene, methoxsalen, trimethylpsoralens, pimecrolimus, 
and tacrolimus) 
Exception: The following topical treatments may be initiated only at Week 24 per 
investigator’s discretion in subjects who have sPGA scores ≥3 (See Section 4.1.4):
x
High potency corticosteroids (WHO Classes I-V), >3% salicylic acid, urea, alpha- or 
beta-hydroxy acids, anthralin, calcipotriene, vitamin D derivatives, retinoids, tazarotene 
Note: Low potency topical steroids (WHO Classes VI and VII) are permitted on the palms, 
soles, face, and intertriginous areas but should not be used within 24 hours prior to any study 
visit. Bland emollients (defined as emollients without urea or alpha or beta hydroxy acids or 
other ingredients which are pharmaceutically active) are allowed on all body regions but should 
not be used within 24 hours prior to any study visit 
10) Any medicated shampoos that contain corticosteroids, coal tar, >3% salicylic acid, or vitamin 
D3 analogues 
Exception: The above shampoos may be initiated only at Week 24 per investigator’s discretion 
in subjects who have 
 (See Section 4.1.4).
11) Live vaccination 
No concomitant medications (prescription, over-the-counter, or herbal) are to be administered 
during the study unless prescribed for treatment of specific clinical events. Any concomitant 
therapies must be recorded on the CRF. 
The investigator should contact and confirm agreement with the Medical Monitor prior to the 
administration of any concomitant medications. 
6.7.2 
Permitted Concomitant Medications 
Stable doses of concomitant medication for chronic medical conditions are permitted as long as 
neither the medication nor the medical condition meet exclusion criteria as detailed in Section 5.2.
Dose adjustments of these medications should be avoided during the study unless clinically 
indicated. If a dose adjustment of these medications should occur, they must be recorded on the 
Concomitant Medications eCRF or the Procedures and Significant Nondrug Therapies eCRF. The 
investigator should instruct the subject to notify the study site about any new treatments he/she 
takes after the start of the study treatment. All medications and significant nondrug therapies 
(including physical therapy and blood transfusions) administered after the subject starts study 
treatment must be listed on the Concomitant Medications eCRF or the Procedures and Significant 
Nondrug Therapies eCRF. 
Note: Low potency topical steroids (WHO Classes VI and VII) are permitted on the palms, soles, 
face, and intertriginous areas but should not be used within 24 hours prior to any study visit. Bland 
emollients (defined as emollients without urea or alpha- or beta-hydroxy acids or other ingredients 
which are pharmaceutically active) are allowed on all body regions but should not be used within 
24 hours prior to any study visit. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
57
6.7.3 
Rescue Medications 
At Week 24, a subject who has an sPGA ≥3 
 may be treated with restricted topicals 
or shampoos, respectively, as described in Section 6.7.1 at the investigator’s discretion. These 
treatments may only be initiated at Week 24, and not at subsequent time points. A subject who is 
initiated on these treatments at Week 24 may use them as needed per the investigator’s judgment 
through Week 52. 
6.8 
Treatment After the End of the Study 
At the end of the study, the investigator should ensure that subjects continue to receive appropriate 
standard of care to treat the condition under study.  
In addition, for subjects who continue to demonstrate clinical benefit, BMS may continue to 
provide study treatment via a rollover extension study requiring approval by responsible health 
authority and ethics committee, or through another mechanism at the discretion of BMS.  
BMS reserves the right to terminate access to BMS supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) the development of BMS-986165 is 
terminated for other reasons including, but not limited to, lack of efficacy and/or not meeting the 
study objectives; c) the subject can obtain medication from a government sponsored or private 
health program. In all cases BMS will follow local regulations. 
7 
DISCONTINUATION CRITERIA 
7.1 
Discontinuation from Study Treatment 
Subjects MUST discontinue IP (and non-IP at the discretion of the investigator) for any of the 
following reasons: 
x
Subject requests to stop study treatment. Subjects who discontinue study treatment early 
should remain in the study for protocol-specified procedures. The only exception to this is 
when a subject specifically withdraws consent for any further contact with him/her or 
persons previously authorized by subject to provide this information. 
x
Any clinically significant AE, laboratory abnormality, or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the 
best interest of the subject. If treatment is discontinued due to an AE, the AE eCRF must 
be completed to show that the AE caused discontinuation. 
x
eGFR <45 mL/min on repeat assessment within 7 days 
x
Abnormal liver tests suggestive of drug-induced liver injury (DILI), as defined in Section 
8.2.8 or if the investigator believes that it is in the best interest of the subject 
x
Subject reports suicidal ideation, suicidal behavior, or suicide attempts at any time after 
randomization, or documents suicidal ideation by answering “Yes” to Question 4 or 5 on 
the eC-SSRS, or documents suicidal behavior on the eC-SSRS at any time during the study. 
The subject should then be immediately referred to a mental health professional for 
evaluation of suicide risk. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
58
x
The subject develops a malignancy, with the exception of a subject who develops 
nonmelanoma skin cancer who may continue in the study at the discretion of the 
investigator 
x
Pregnancy, positive pregnancy test, or subject expresses an interest in becoming pregnant 
(refer to Section 8.2.6) 
x
Subject develops active TB during the study or prematurely discontinues treatment for 
LTBI, or subject is noncompliant with LTBI therapy (refer to Section 8.4.4) 
x
Termination of the study or program by BMS 
x
Unblinding of a subject’s treatment assignment for any reason (emergency or 
nonemergency) 
x
Inability or failure to comply with protocol requirements in the opinion of the investigator 
x
Loss of ability to freely provide consent through imprisonment or involuntary incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness 
Refer to the Schedule of Activities (Section 1.3) for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations that can be completed. 
All subjects who discontinue BMS-986165 should comply with protocol-specified follow-up 
procedures as outlined in Section 1.3. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness). Replacement of subjects is not permitted. 
If study treatment is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate eCRF page. 
7.1.1 
Temporary Discontinuation of Study Medication 
Temporary study treatment discontinuation is only allowed if the subject develops an AE which, 
in the opinion of the investigator, indicates that it is in the subject’s best interest that the study 
treatment be placed on hold. Study treatment in this situation should be stopped until the AE is 
medically treated and has resolved per principal investigator’s judgment.
Any temporary study treatment discontinuation as well as restart must be documented on the 
corresponding eCRF. 
7.1.2 
Post-Study Treatment Study Follow-Up
Post-study follow-up is of critical importance and is essential to preserving subject safety and the 
integrity of the study. Subjects who discontinue study treatment must continue to be followed for 
collection of outcomes and/or survival follow-up data as required and in line with Section 4 until 
death or the conclusion of the study. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
59
Subjects who discontinue study treatment should be encouraged to undergo all study-related visits 
for the full treatment period in order to support the final efficacy and safety analysis. 
7.2 
Discontinuation from the Study 
Subjects who request to discontinue study treatment will remain in the study and must continue to 
be followed for protocol-specified follow-up procedures as specified in Section 1.3. The only 
exception to this is when a subject specifically withdraws consent for any further contact with 
him/her or persons previously authorized by subject to provide this information.  
x
Subjects should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible. 
x
The withdrawal of consent should be explained in detail in the medical records by the 
investigator and entered on the appropriate CRF page. 
x
In the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law. 
x
If the subject withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
7.3 
Lost to Follow-Up
x
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status. This includes follow-up with persons authorized by the subject. 
x
Lost to follow-up is defined by the inability to reach the subject after a minimum of three
documented phone calls, faxes, or emails as well as lack of response by subject to one 
registered mail letter. All attempts should be documented in the subject’s medical records.
x
If it is determined that the subject has died, the site will use permissible local methods to obtain 
date and cause of death. 
x
If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the subject’s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary to complete the follow-up portion of the 
study. 
x
The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information. 
x
If after all attempts, the subject remains lost to follow-up, then the last known alive date as 
determined by the investigator should be reported and documented in the subject’s medical 
records. 
8 
STUDY ASSESSMENTS AND PROCEDURES 
x
Study procedures and timing are summarized in the Schedule of Activities (Section 1.3) and 
described in Section 4.1.  
x
Protocol waivers or exemptions are not allowed. 
x
All significant safety concerns must be discussed with the Medical Monitor immediately upon 
occurrence or awareness to determine if the subject should continue or discontinue treatment. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
60
x
Adherence to the study design requirements, including those specified in the Schedule of 
Activities (Section 1.3), is essential and required for study conduct. 
x
All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria before randomization. Randomization should not occur until at least 
8 days after the Screening Visit to allow collection of PSSD data during screening in order to 
calculate a baseline PSSD score. The investigator will maintain a screening log to record details 
of all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable. 
x
Procedures conducted as part of the subject’s routine clinical management (eg, blood count) 
and obtained before signing of informed consent may be utilized for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities (Section 1.3).
x
For several assessments, appropriate training will be provided to investigators and designated 
personnel at sites. Only those individuals trained and certified to perform these assessments 
will be performing them during the study. 
8.1 
Efficacy Assessments 
Every effort must be made to ensure that the same evaluator(s) complete the assessment for each 
subject. If the evaluator(s) is unable to complete the evaluation, then a qualified individual with 
overlapping experience may perform the evaluation. Documentation of who performed the 
evaluation is to be recorded in source documents. Assessments are to be performed at 
approximately the same time of day throughout the duration of the study.  
Baseline assessments must be performed per protocol (standard of care assessments may not be 
used for baseline). Procedures not specified in the protocol that are part of standard care may be 
performed if they do not interfere with study procedures; any data arising from such procedures 
are not to be reported in the eCRF. 
8.1.1 
Investigator-Administered Assessments 
8.1.1.1 
static Physician’s Global Assessment (sPGA)
The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, 
scale, and induration.25 The sPGA measure determines psoriasis severity at a single point in time 
(without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), 
moderate (3), or severe (4). All sPGA assessments should be performed by a trained physician (eg 
dermatologist) or appropriately trained investigator who is experienced in the assessment of 
psoriasis patients. Every effort should be made to ensure that the physician or designee who 
performed the sPGA evaluations for a subject at randomization performs the sPGA for that subject 
at all subsequent visits (see APPENDIX 5).
8.1.1.2 
Psoriasis Area and Severity Index (PASI) 
The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions 
(each graded on a 0–4 scale), weighted by the area of involvement (head, arms, trunk to groin, and 
legs to top of buttocks).26 The PASI produces a numeric score that can range from 0 to 72, with 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
61
higher PASI scores denoting more severe disease activity. The PASI can also be used to assess 
response to treatment. The PASI 50 is the proportion of subjects who experience at least a 50% 
improvement in PASI score as compared with the baseline value. The PASI 75, PASI 90, and 
PASI 100 are defined similarly. BMS will host a training session prior to initiation of the study to 
demonstrate proper PASI scoring. All PASI assessments should be performed by a trained 
physician (dermatologist) or appropriately trained investigator who is experienced in the 
assessment of psoriasis patients (see APPENDIX 6).  
8.1.1.3 
Body Surface Area (BSA) 
Measurement of psoriasis BSA involvement is estimated using the handprint method with the size 
of a subject’s handprint (including fingers and thumb) representing 1% of BSA involved.27,28,29
The total BSA = 100% with breakdown by body region as follows: head and neck = 10% 
(10 handprints), upper extremities = 20% (20 handprints), trunk including axillae  and groin = 30% 
(30 handprints), lower extremities including buttocks = 40% (40 handprints). All BSA assessments 
should be performed by a dermatologist or appropriately trained investigator who is experienced 
in the assessment of psoriasis patients. 
8.1.1.4 
scalp specific Physician’s Global Assessment (ss-PGA) 
For this assessment in subjects with scalp involvement,30 scalp lesions are evaluated in terms of 
clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA 
scale:
0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease. 
The ss-PGA should be performed by a dermatologist or appropriately trained investigator who is 
experienced in the assessment of psoriasis patients. An example of the ss-PGA is provided in 
APPENDIX 7. 
8.1.1.6 
Physician’s Global Assessment-Fingernails (PGA-F)
In this assessment,32 the overall condition of the fingernails is rated on a 5-point scale: 
0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe 
The PGA-F will be performed only in subjects with psoriatic fingernail involvement to assess 
severity and subsequent improvement. An example is provided in APPENDIX 9. The PGA-F
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
62
should be performed by a dermatologist or appropriately trained investigator who is experienced 
in the assessment of psoriasis patients. 
8.1.1.8 
Palmoplantar PGA (pp-PGA) 
This measure will be used for subjects with palmoplantar involvement at baseline.34 The pp-PGA 
uses a 5-point (0-4) scale:   
0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe (see APPENDIX 11). 
The pp-PGA should be performed by a dermatologist or appropriately trained investigator who is 
experienced in the assessment of psoriasis patients. 
8.1.2 
Subject-Reported Assessments 
8.1.2.1 
Psoriasis Symptoms and Signs Diary (PSSD) 
The PSSD is an 11-item subject-reported instrument that assesses severity of symptoms and 
subject-observed signs commonly associated in plaque psoriasis.36,37 It has been shown to be 
reliable and valid in measuring symptoms and signs of subjects with moderate-to-severe plaque 
psoriasis in the clinic and has strong psychometric properties in assessing treatment effects in 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
63
clinical trials.38 The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin 
tightness) and 6 subject-observed signs (skin dryness, cracking, scaling, shedding or flaking, 
redness, bleeding) using 0–10 numerical ratings. The severity of each item is rated on an 11-point 
numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Two versions of the PSSD 
were developed, one with a 24-hour recall period (PSSD-24h) and one with a 7-day recall period. 
The PSSD-24h will be administered daily in this trial to avoid recall bias with a longer recall period 
(see APPENDIX 13).
8.1.2.4 
Dermatology Life Quality Index (DLQI) 
The DLQI39 is a subject-reported quality of life index which consists of 10 questions concerning 
symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment 
during the last week. Each question is scored on a scale of 0 to 3 by a tick box: 0 - "not at all", 
1 -- "a little", 2 - "a lot", or 3 - "very much". The scores are summed, giving a range from 0 (no 
impairment of life quality) to 30 (maximum impairment) (see APPENDIX 14).
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
64
 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
65
8.1.2.11 
Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire 
The PASE questionnaire will be administered at Screening in subjects with peripheral joint 
complaints. The PASE questionnaire is a self-administered tool that is used to screen for psoriatic 
arthritis among subjects who have psoriasis. The PASE questionnaire consists of 15 questions 
subdivided into 7 questions focusing on symptoms of psoriatic arthritis, and 8 questions focusing 
on the impact of psoriatic arthritis on function. Each question is scored on a 1 to 5 scale, with a 
maximum score of 75. A score of 47 or above has been shown to distinguish between psoriatic 
arthritis and non-psoriatic arthritis.46 This questionnaire is only intended to be a screening tool for 
psoriatic arthritis and does not replace a comprehensive musculoskeletal exam performed by a 
rheumatologist. The PASE questionnaire should take 6 to 10 minutes to complete and is only done 
at Screening (See APPENDIX 21).
8.2 
Adverse Events 
The definitions of an AE and SAE can be found in APPENDIX 3. 
All AEs will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or the 
subject's legally authorized representative).  
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the subject to 
discontinue before completing the study.  
Contacts for SAE reporting are specified in APPENDIX 3. 
8.2.1 
Adverse Events of Interest 
Adverse events of interest (AEIs) are AEs for a particular product or class of products that a 
Sponsor may wish to monitor carefully. Adverse events of interest may be serious or nonserious. 
Such events may require further investigation  to better characterize and understand them. In the 
BMS-986165 clinical development program, certain skin-related AEs (eg, acne), infection AEs, 
and CK elevation have been identified as potential AEIs; however, there has been no definitive 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
66
assessment on the causal relationship between these events and treatment with BMS-986165. 
Additionally, given a potential association between treatment for autoimmune diseases and 
increased risk for cancer, malignancy has been identified as a potential AEI. Therefore, additional 
information about certain skin-related AEs, infection AEs, CK elevation, and malignancy may be 
collected on the case report form in order to better characterize and understand them. 
8.2.2 
Time Period and Frequency for Collecting AE and SAE Information 
The collection of nonserious AE information should begin at initiation of study treatment until 
discharge from the study (ie, final study visit for a given subject), at the timepoints specified in the 
Schedule of Activities (Section 1.3).  
The Reference Safety Information in Sections 5.6.1 and 5.6.2 of the IB should be used to determine 
expectedness of SAEs for expedited reporting. Following the subject’s written consent to 
participate in the study, all SAEs, whether related or not related to study drug, must be collected, 
including those thought to be associated with protocol-specified procedures. 
All SAEs must be collected from the date of subject’s written consent until 30 days after the final 
dose of the study drug or subject’s participation in the study if the last scheduled visit occurs at a 
later time. Monitoring for SAEs will occur at every study visit.  
x
The investigator must report any SAE that occurs after these time periods and that is believed 
to be related to study drug or protocol-specified procedure. Medical occurrences that begin 
before the start of study treatment but after obtaining informed consent will be recorded on the 
appropriate section of the CRF. 
x
All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in APPENDIX 3.  
x
The investigator will submit any updated SAE data to the Sponsor within 24 hours of this being 
available. 
Investigators are not obligated to actively seek AEs or SAEs in former study subjects. However, 
if the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the study treatment 
or study participation, the investigator must promptly notify the Sponsor. 
The method of evaluating and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in APPENDIX 3. 
8.2.3 
Method of Detecting AEs and SAEs 
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs). 
8.2.4 
Follow-up of AEs and SAEs 
x
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see APPENDIX 3).
x
Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
67
x
All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF. Completion of supplemental CRFs may be requested for AEs and/or laboratory 
abnormalities that are reported/identified during the course of the study. 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up (as defined 
in Section 7.3).
Further information on follow-up procedures is given in APPENDIX 3. 
8.2.5 
Regulatory Reporting Requirements for SAEs 
x
Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities toward the safety of subjects and the safety of a product 
under clinical investigation are met. 
x
An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
Sponsor or designee will be reporting AEs to regulatory authorities and ethics committees 
according to local applicable laws including European Directive 2001/20/EC and FDA Code of 
Federal Regulations 21 CFR Parts 312 and 320. A SUSAR (Suspected, Unexpected Serious 
Adverse Reaction) is a subset of SAEs and will be reported to the appropriate regulatory authorities 
and investigators following local and global guidelines and requirements. 
8.2.6 
Pregnancy 
In the event a subject becomes pregnant during the trial, the study treatment must be discontinued 
immediately. If the subject becomes pregnant while on treatment or within 3 days of discontinuing 
study treatment, the investigator must immediately notify 
 Drug Safety of this event and 
complete and forward a Pregnancy Surveillance Form to 
 Drug Safety within 24 hours of 
awareness of the event and in accordance with SAE reporting procedures described in APPENDIX 
3. The investigator must also notify the Medical Monitor or designee of this event within 24 hours 
of awareness of pregnancy.  
The pregnant subject will need to be followed up until the conclusion of the pregnancy for 
pregnancy outcomes. The safety data of the subject will continue to be collected under the same 
rules as instructed in Section 7.1.
Any pregnancy that occurs in a female partner of a male study subject should be reported to 
 
Drug Safety. In order for Sponsor or designee to collect any pregnancy surveillance information 
from the female partner, the female partner must sign an ICF for disclosure of this information. 
Information on this pregnancy will be collected on the Pregnancy Surveillance Form. 
8.2.7 
Laboratory Test Result Abnormalities 
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
68
x
Any laboratory test result that is clinically significant or meets the definition of an SAE  
x
Any laboratory test result abnormality that required the subject to have study treatment 
discontinued or interrupted 
x
Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy 
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia vs low hemoglobin value). 
8.2.8 
Potential Drug-Induced Liver Injury (DILI) 
All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs (see 
Section 8.2 and APPENDIX 3 for reporting details). Wherever possible, timely confirmation of 
initial liver-related laboratory abnormalities should occur prior to the reporting of a potential DILI 
event. 
Potential DILI is defined as:  
1) ALT or AST elevation >3 times ULN 
AND
2) Total bilirubin >2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase), 
AND
3) No other immediately apparent possible causes of liver function test elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, preexisting chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic. 
8.2.9 
Other Safety Considerations 
Any significant worsening of a preexisting medical condition noted during interim or final PE, 
ECG, x-ray filming, any other potential safety assessment required or not required by protocol 
should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly. 
8.3 
Overdose 
For this study, taking more than 2 days’ worth of study treatment within a 24-hour time period will 
be considered an overdose. 
In the event of an overdose the investigator should: 
1) Contact the Medical Monitor immediately 
2) Closely monitor the subject for AEs/SAEs and laboratory abnormalities  
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the subject. 
8.4 
Safety 
Planned time points for all safety assessments are listed in the Schedule of Activities (Section 1.3). 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
69
8.4.1 
Physical Examinations 
A complete physical examination will include general appearance, vital signs, eyes, ears, nose 
mouth, throat, neck, respiratory, cardiovascular, respiratory, GI/abdomen, lymphatic, 
musculoskeletal, skin, psychiatric, and neurologic exams. A targeted physical examination will 
include any organ system associated with an AE or a laboratory abnormality. 
8.4.2 
Vital Signs 
Refer to Schedule of Activities (Section 1.3).
8.4.3 
Electrocardiograms 
A 12-lead ECG will be performed at the visits indicated in the schedule of activity (Section 1.3).
The patient will remain supine for 5-10 minutes prior to the ECG and must have their lab work 
done after the tracing so that the ECG results remain as accurate as possible. The ECG  results will 
be read by the primary study investigator or a designee. 
8.4.4 
Tuberculosis Screening and Chest Imaging
Chest imaging results and PE are part of the process to assess a subject’s eligibility, as outlined in 
Section 1.3 and as defined in exclusion criterion 3.c (Section 5.2). Chest imaging (eg, chest x-ray, 
chest CT scan) at the Screening Visit is required if not already performed and documented within 
6 months of obtaining written informed consent. A subject must not have active signs or symptoms 
of TB, as judged by the investigator, to be eligible for the study. 
In addition to a complete PE and medical history to evaluate exposure to TB, all subjects will have 
a screening test, an IGRA (eg, QuantiFERON®-TB Gold) performed centrally. If unable to obtain 
central laboratory results, an IGRA test could be obtained locally, after consultation with the 
 
Medical Monitor. A subject with an indeterminate IGRA test result must be retested for 
confirmation. If the second result is again indeterminate, the subject will be excluded from the 
study. If the second result is positive, the subject should be considered as having LTBI provided 
there are no signs or symptoms of active TB. If the second result is negative, the subject may be 
eligible provided no other exclusion criterion for TB is met. 
8.4.5 
Clinical Safety Laboratory Assessments 
Investigators must document their review of each laboratory safety report. 
Hematology
Hemoglobin (Hgb)
Hematocrit (Hct)
White Blood Cell Count, including differential
Platelet Count
Chemistry
AST
ALT
Total Bilirubin
Total Protein
Albumin
Sodium
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
70
Direct Bilirubin (if total bilirubin >ULN) 
Alkaline Phosphatase
Lactate Dehydrogenase (LDH)
Creatinine
Blood Urea Nitrogen (BUN)
Uric Acid 
Glucose (fasting at some visits)
Potassium
Chloride
Calcium
Phosphorus
Creatine Kinase (CK)*
Estimated Glomerular Filtration Rate (eGFR)
Urinalysis
Protein
Glucose
Blood
Leukocyte Esterase
Specific Gravity
pH
Microscopic Examination (reflex if abnormal)
Lipid Panel
Cholesterol (total)
High Density Lipoprotein (HDL)
Low Density Lipoprotein (LDL)
Triglycerides 
Infectious Serologies
Hepatitis C Antibody with reflex to Hepatitis C RNA if positive
Hepatitis B Surface Antigen (HBsAg)
Hepatitis B Surface Antibody (HBsAb)
Hepatitis B Core Antibody (HBcAb)
Hepatitis B DNA Viral Load (HBV DNA)
HIV-1 and -2 antibody 
Other Analyses
Pregnancy test (WOCBP only: serum hCG test at Screening, followed by urine hCG test every 
4 weeks)
Follicle-Stimulating Hormone (FSH) (to confirm menopausal status [see APPENDIX 4], at 
screening)
Hemoglobin A1C 
Thyroid-Stimulating Hormone (TSH)
x
If TSH above normal reference range, test free T4; if TSH below normal range, test 
free T4 & T3
High-Sensitivity C Reactive Protein (hs-CRP)
Serum Immunoglobulins (IgM, IgG, IgA, IgE)
*If CK > 2.5 × ULN, then reflex testing (ie, CK-MB, Troponin I) will be required. 
8.4.5.1 
Estimated Glomerular Filtration Rate (eGFR) 
Glomerular filtration rate will be estimated using the Modification of Diet in Renal Disease 
(MDRD) equation at screening and during the study at select visits. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
71
The MDRD equation is as follows:47
eGFR = 175 × standardized SCr−1.154 × age−0.203 × 1.212 [if black] or 0.742 [if female] 
Note: GFR is expressed as mL/min/1.73 m2 of body surface area and SCr (serum creatinine) is expressed in mg/dL. 
Subjects with an eGFR <45 mL/min will be excluded from participation. 
8.4.6 
Depression Monitoring 
Depression will be monitored by administration of the eight-item Patient Health Questionnaire 
(PHQ-8) at Screening and during visits as outlined in Section 1.3.
8.4.6.1 
Eight-Item Patient Health Questionnaire (PHQ-8)
The PHQ-8 is established as a valid diagnostic and severity measure for depressive disorders in 
large clinical studies.48 Each of the 8 questions is based on a 2-week recall and scored on a scale 
of 0 to 3 by a tick box as: Not at All, Several Days, More than Half the Days, and Nearly Every 
Day. A score of ≥10 is suggestive of moderate depressive symptoms (see APPENDIX 22).49 If a 
subject scores ≥15 on the PHQ-8 during the study, the investigator will review the situation and 
refer the subject to a mental health professional if deemed necessary. 
8.4.7 
Suicidal Ideation and Behavior (SIB) Monitoring 
Subjects in this clinical trial will be monitored for SIB by the eC-SSRS (Section 8.4.7.1) at the 
visits outlined in the Schedule of Activities (Section 1.3). Subjects who answer yes to Questions 4 
or 5 which indicates a suicidal ideation severity level of 4 or 5 or document suicidal behavior or 
suicidal attempts on the eC-SSRS will have their treatments discontinued and be immediately 
referred to a mental health professional for further evaluation. In addition, family members or 
caregivers of the subjects will be instructed to immediately report any suicidal ideation, suicidal 
behavior, or suicide attempt to the investigator. 
8.4.7.1 
electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) 
The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) is a computer-automated, 
patient-reported version of the C-SSRS instrument that defines 11 categories of SIB events.50,51,52
The categories are as follows: 
x
Suicidal ideation 
1. Passive 
2. Active: Nonspecific (no method, intent, or plan) 
3. Active: Method, but no intent or plan 
4. Active: Method and intent, but no plan 
5. Active: Method, intent, and plan 
x
Suicidal behavior 
1. Completed suicide 
2. Suicide attempt 
3. Interrupted attempt 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
72
4. Aborted attempt 
5. Preparatory actions toward imminent suicidal behaviors 
x
Self-injurious behavior, no suicidal intent 
APPENDIX 23 provides definitions of these categories.53
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
73
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
74
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
75
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
76
8.7 
Health Economics OR Medical Resource Utilization and Health 
Economics 
Health Economics/Medical Resource Utilization and Health Economics parameters will not be 
evaluated in this study. 
9 
STATISTICAL CONSIDERATIONS 
9.2 
Populations for Analyses 
For purposes of analysis, the following analysis sets will be used in this trial: 
Enrolled Population: All subjects who sign informed consent. 
Full Analysis Set (FAS): All subjects who were randomized to receive assigned study treatment.
Following the intent-to-treat principle, subjects will be analyzed according to the treatment group 
assigned at randomization. The FAS will be the primary efficacy analysis population. 
Per Protocol Set (PPS): A subset of the FAS who are compliant with study treatment and who 
do not have any relevant protocol deviations that may impact the coprimary efficacy endpoint 
assessments (Section 9.6.3). The PPS will be analyzed for the coprimary endpoint comparisons 
according to the treatment assigned at randomization.  
As-treated Population:  All randomized subjects who take at least one dose of study treatment. 
Subjects will be analyzed according to treatment received. The As-treated population will be for 
safety analyses. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
77
9.3 
Endpoints  
9.3.1 
Primary Endpoints 
The coprimary efficacy endpoints for BMS-986165 compared to placebo at Week 16 are defined 
as: 
x
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 
x
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement 
from baseline in the PASI score 
9.3.2 
Secondary Endpoints 
9.3.2.1 
Key Secondary Endpoints for Comparisons to Placebo 
The key secondary endpoints for BMS-986165 compared to placebo at Week 16 are defined as: 
x
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement 
from baseline in the PASI score 
x
PASI 100 response assessed as a proportion of subjects who achieve a 100% improvement 
from baseline in the PASI score 
x
sPGA 0 response assessed as a proportion of subjects with an sPGA score of 0 
x
Change from baseline in PSSD symptom score 
x
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score 
of 0 among subjects with a baseline PSSD symptom score ≥1
x
ss-PGA 0/1 assessed as a proportion of subjects with a ss-PGA score 0 or 1 among subjects 
with a baseline ss-PGA score ≥3
x
DLQI 0/1 assessed as a proportion of subjects with a DLQI score of 0 or 1 among subjects 
with a baseline DLQI score ≥2
x
PGA-F 0/1 assessed as a proportion of subjects with a PGA-F score of 0 or 1 among 
subjects with a baseline PGA-F score ≥3
x
pp-PGA 0/1 assessed as a proportion of subjects with a pp-PGA score of 0 or 1 among 
subjects with a baseline pp-PGA score ≥3
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
78
9.3.2.2 
Key Secondary Endpoints for Comparisons to Apremilast 
The key secondary endpoints for BMS-986165 compared to apremilast at Week 16 are defined as: 
x
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement 
from baseline in the PASI score 
x
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement 
from baseline in the PASI score 
x
PASI 100 response assessed as a proportion of subjects who achieve a 100% improvement 
from baseline in the PASI score 
x
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 
x
sPGA 0 response assessed as a proportion of subjects with an sPGA score of 0 
x
Change from baseline in PSSD symptom score 
x
PSSD symptom score of 0 assessed as a proportion of subjects with a PSSD symptom score 
of 0 among subjects with a baseline PSSD symptom score ≥1
x
ss-PGA 0/1 assessed as a proportion of subjects with a ss-PGA score 0 or 1 among subjects 
with a baseline ss-PGA score ≥3
The key secondary endpoints for BMS-986165 compared to apremilast both at Week 52 and 
Week 24 are defined as: 
x
PASI 75 response assessed as a proportion of subjects who achieve a 75% improvement 
from baseline in the PASI score 
x
PASI 90 response assessed as a proportion of subjects who achieve a 90% improvement 
from baseline in the PASI score 
x
sPGA 0/1 response assessed as a proportion of subjects with an sPGA score of 0 or 1 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
79
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
80
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
81
9.4 
Efficacy Analyses 
Categorical data will be summarized as frequency counts and percentages. Continuous data will 
be summarized using n, mean, standard deviation, median, minimum, and maximum unless 
otherwise specified. Efficacy variables will be summarized for all visits in which the variable is 
assessed. Complete details of the planned analyses will be documented in the statistical analysis 
plan and finalized before database lock. 
During the first 16 weeks of treatment, data will be presented for the following treatments: 
x
BMS-986165 6 mg QD 
x
Apremilast 30 mg BID 
x
Placebo 
After Week 16, data will be presented for the following treatments: 
x
BMS-986165 6 mg QD 
x
Apremilast 30 mg BID 
x
Placebo→BMS-986165 6 mg QD (starting from Week 16 through Week 52) 
x
All BMS-986165 6 mg QD (all subjects exposed to BMS-986165 6 mg QD; includes 
subjects on placebo and apremilast 30 mg BID that switched to BMS-986165 6 mg QD) 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
82
9.4.1 
Coprimary Endpoint Analyses 
The analysis model for the coprimary efficacy endpoints, sPGA 0/1 and PASI 75 
(responder/nonresponder) at Week 16, will use stratified Cochran-Mantel-Haenszel (CMH) tests 
stratified by the stratification factors used for randomization (see Section 4.1.2) to compare the 
response rates of BMS-986165 6 mg QD to placebo using the Week 16 data of the FAS. If expected 
cell counts are not sufficient for each strata level, then strata levels will be combined for the 
analysis. The odds ratio (ratio of odds in BMS-986165 6 mg QD group to the odds in placebo 
group) and the corresponding 2-sided 95% confidence interval (CI) will be provided. Estimates of 
proportions and their 2-sided 95% CIs will be provided.
9.4.1.1 
Imputation Methods for Coprimary Endpoints 
Nonresponder imputation (NRI) will be used for coprimary efficacy endpoints for subjects who 
discontinue study or treatment of study prior to Week 16, start a protocol prohibited 
medication/therapy that could improve psoriasis during the first 16 weeks of treatment, or who 
have otherwise missing endpoint data at the specified timepoint. The NRI will the primary method 
of imputation for the coprimary efficacy endpoints. 
9.4.1.2 
Sensitivity Analyses for the Coprimary Endpoints 
The following imputation methods will be used in sensitivity analyses of the coprimary efficacy 
endpoints: 
x
Last observation carried forward (LOCF) for subjects with missing values at Week 16 
x
For subjects with missing values at Week 16, LOCF will be used for placebo subjects and 
NRI will be used for BMS-986165 6 mg QD subjects. This will include subjects who 
discontinue early, start a protocol prohibited medication/therapy prior to Week 16 that 
could improve psoriasis, or who have otherwise missing endpoint data at Week 16 
9.4.1.3 
Supportive Analyses for the Coprimary Endpoints 
The coprimary efficacy endpoints will also be analyzed using the Week 16 data of the PPS using 
the analysis described in Section 9.4.1 and the imputation methods described in Section 9.4.1.1.
Additionally, the coprimary efficacy endpoints for the FAS will be analyzed with a logistic 
regression model with treatment and the stratification factors used for randomization as covariates. 
9.4.1.4 
Subgroup Analyses for the Coprimary Endpoints 
Subgroup analyses will be conducted for the coprimary efficacy endpoints for the FAS using the 
analysis described in Section 9.4.1 and the imputation methods described in Section 9.4.1.2.
Subgroups to be evaluated will include the following: 
x
Gender 
x
Age categories (<65; ≥65)
x
Race 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
83
x
Body weight categories (<90 kg; ≥90 kg)
x
Prior biologic use (yes/no) 
x
Prior systemic treatment of psoriasis (yes/no) 
x
Geographic region 
In addition, additional subgroups defined for descriptive summaries will be specified in the 
statistical analysis plan. 
9.4.2 
Secondary Endpoint Analyses 
The analysis model for the binary secondary endpoints will use stratified CMH tests stratified by 
the stratification factors used for randomization (see Section 4.1.2) to compare the response rates 
of BMS-986165 6 mg QD to placebo or apremilast for the FAS. If expected cell counts are not 
sufficient for each strata level, then strata levels will be combined for the analysis. The odds ratio 
(ratio of odds in BMS-986165 6 mg QD group to the/odds in placebo group or active comparator 
group), and the corresponding 2-sided 95% CI will be provided. 
The analysis model for continuous secondary endpoints will use analysis of covariance 
(ANCOVA) 
, with treatment and stratification factors 
used for randomization as fixed effects. The baseline value will be added into the model as a 
covariate. Treatment differences based on least-squares (LS) means and the corresponding 2-sided 
95% CIs will be provided for the difference between BMS-986165 6 mg QD and placebo or active 
comparator depending on the endpoint being assessed. 
9.4.2.1 
Imputation Methods for Secondary Endpoints 
The NRI will be applied to the analyses of binary secondary efficacy endpoints for subjects who 
discontinue early, start a protocol prohibited medication/therapy that could improve psoriasis, or 
who have otherwise missing endpoint data prior to the specified timepoint.  
For continuous secondary efficacy endpoints, a modified baseline observation carried forward 
(mBOCF) will be used for missing data. The baseline observation will be carried forward for 
subjects who discontinue study treatment due to: 
x
Lack of efficacy 
x
AEs 
and for subjects who start a protocol prohibited medication/therapy that could improve psoriasis 
prior to the endpoint. The last valid observation will be carried forward for all other subjects with 
missing data. 
At Week 24, subjects originally randomized to apremilast 30 mg BID who do not achieve PASI 50 
response will be switched in a blinded manner to BMS-986165 6 mg QD. These subjects will be 
considered nonresponders to apremilast for the timepoints after the switch for the binary endpoints 
for the Week 52 comparisons. The mBOCF described above will be used for the continuous 
endpoints. Subjects will be analyzed according to their original randomized treatment group. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
84
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
85
9.4.4 
Time-to-Event Endpoints 
The Kaplan-Meier product limit method will be used to estimate the distribution curve for 
time-to-loss (from Week 24) of PASI 75 response for the BMS-986165 treatment group. 
9.5 
Safety Analyses 
Safety data will be analyzed for AEs, SAEs, laboratory analytes, vital signs, ECGs, and suicidality 
and depression. Safety will be summarized using the As-treated population. Categorical data will 
be summarized as frequency counts and percentages. Continuous data will be summarized using 
n, mean, standard deviation, median, minimum, and maximum unless otherwise specified. 
During the first 16 weeks of treatment, data will be presented for the following treatments: 
x
BMS-986165 6 mg QD 
x
Apremilast 30 mg BID 
x
Placebo 
After Week 16, data will be presented for the following treatments: 
x
BMS-986165 6 mg QD 
x
Apremilast 30 mg BID 
x
Placebo to BMS-986165 6 mg QD (starting from Week 16 through Week 52) 
x
All BMS-986165 6 mg QD (all subjects exposed to BMS-986165 6 mg QD; includes 
subjects on placebo that switched to BMS-986165 6 mg QD) 
9.5.1 
Adverse Events 
Treatment-emergent adverse events (TEAEs), SAEs and deaths, and AEs leading to study 
treatment discontinuation, AEs by maximum severity, and AEs by relationship will be summarized 
by the MedDRA system organ class and preferred term. All TEAEs, AEIs, as well as each AE 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
86
adjudicated category (ie, infections, cardiovascular, and SIB) will also be summarized by preferred 
term sorted by decreasing frequency.  
9.5.2 
Vital Signs and ECGs 
Vital signs and ECGs will be summarized as raw, change from baseline, and change from 
maximum postbaseline value. Incidence of abnormal ECG findings will also be summarized. 
9.5.3 
Clinical Laboratory Tests 
Laboratory analytes will be summarized as raw, change from baseline, and change from maximum 
postbaseline value. Incidence of abnormal, high, or low values will be summarized. 
9.5.4 
Suicidality and Depression Assessments 
Suicidality and depression will be assessed using eC-SSRS and PHQ-8. Data will be summarized, 
as applicable.   
9.6 
Other Analyses  
9.6.1 
Demographics and Baseline Data 
Demographics and baseline data will be summarized by treatment for each applicable analysis 
population. Categorical data will be summarized as frequency counts and percentages. Continuous 
data will be summarized using n, mean, standard deviation, median, minimum, and maximum 
unless otherwise specified. 
9.6.2 
Prior and Concomitant Medications 
Prior and concomitant medications, categorized by medication group and subgroup according to 
the World Health Organization (WHO) Drug Dictionary, will be summarized by treatment for the 
As-treated population. Medications with an end date prior to the first dose of study drug will be 
considered prior medications. 
9.6.3 
Relevant Protocol Deviations 
Relevant protocol deviations are deviations that can have an impact on the primary efficacy 
endpoints. The impact of relevant protocol deviations on the primary efficacy results will be 
assessed by excluding subjects from the FAS to define the PPS in supportive analyses of the 
primary efficacy endpoints. Relevant protocol deviations to be considered regarding exclusion of 
subjects from the FAS will include the following: 
x
Subject randomized but did not take any study treatment 
x
Subject failed to meet any study inclusion criteria but was randomized to receive study 
treatment 
x
Subject met a study exclusion criterion which may have an impact on the coprimary 
efficacy endpoints but was randomized to receive study treatment 
x
Subject noncompliant with study treatment within the first 16 weeks of treatment; defined 
as <80% compliant with study treatment 
x
Subject took prohibited concomitant medication prior to Week 16 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
87
x
Subject received treatment different to intended treatment at any visit prior to Week 16 
All subjects with relevant protocol deviations will be identified prior to database lock. Relevant 
protocol deviations will be summarized by treatment group and deviation category for the FAS 
population.  
9.7 
Interim Analyses 
No interim analysis is currently planned. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
88
10 
REFERENCES 
1  Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic 
review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85.
2  Kupetsky EA, Keller M. Psoriasis vulgaris: an evidence-based guide for primary care. J Am 
Board Fam Med 2013;26(6):787-801. 
3  World Health Organization. Global Report on psoriasis. WHO 2016. 
4  Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis 2005;64(Suppl II):ii18-ii23.
5  Queiro R, Tejón P, Alonso S, Coto P. Age at disease onset: a key factor for understanding 
psoriatic disease. Rheumatology (Oxford) 2014;53(7):1178-85. 
6  Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe 
psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan;303(1):1-10.
7  Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much 
disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
8  Nestle FO, Kaplan DH, Barker J. Mechanisms of Disease: Psoriasis. N Engl J Med 
2009;361:496-509.
9  Mehta NN, Afzar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe 
psoriasis are at increased risk of cardiovascular mortality: cohort study using the General 
Practice Research Database. European Heart J 2010;31:1000–1006.
10  Novartis. Rheumatrex® (methotrexate). United States Prescribing Information. 2016. 
11  Novartis. Neoral® (cyclosporine). United States Prescribing Information. 2009. 
12  Celgene. Otezla® (apremilast). United States Prescribing Information. 2017. 
13  Abbvie. Humira® (adalimumab). United States Prescribing Information. 2017. 
14  Janssen Biotech. Remicade® (infliximab). United States Prescribing Information. 2013. 
15  Janssen Biotech. Stelara® (ustekinumab). United States Prescribing Information. 2016. 
16  Novartis. Cosentyx® (sekukinumab). United States Prescribing Information. 2015. 
17  Eli Lilly. Taltz® (ixekizumab). United States Prescribing Information. 2017. 
18  Valeant. Siliq® (brodalumab). United States Prescribing Information. 2017. 
19  Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, Treatment 
Trends, and Treatment Dissatisfaction Among Subjects with Psoriasis and Psoriatic Arthritis 
in the United States. Findings from the National Psoriasis Foundation Surveys, 2003-
2011. JAMA Dermatol 2013;149(10):1180–1185.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
89
20  Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the 
immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-56.
21  Tokarski JS, Zupa-Fernandez A, Tredup JA, et al.. Tyrosine Kinase 2-Mediated Signal 
Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of its 
Pseudokinase Domain. J Biol Chem 2015;290:11061-11074.
22  Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain 
underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad 
Sci U S A. 2003;100:11594-11599.
 
 
 
 
24  Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis 
Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of 
psoriasis. J Am Acad Dermatol 2004;50:859-66.
25  Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 
2005;64:ii65-ii68. 
26  Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 
1978;157(4):238-44. 
27  Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns. 1996;22:230-1.
28  Thomas CL, Finlay AY. The 'handprint' approximates to 1% of the total body surface area 
whereas the 'palm minus the fingers' does not. Br J Dermatol. 2007;157(5):1080-1.
29  Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch 
Dermatol. 1992;128:1129–30.
30  Kragballe K, Menter A, Lebwohl M, et al. Long-term management of scalp psoriasis: 
perspectives from the international psoriasis council. J Dermatol Treat. 2013;24:188-192.
 
 
 
 
32  Tan EST, Chong W-S, Liang Tey H. Nail psoriasis: a review. Am J Clin Dermatol. 
2012;13:375-388.
 
 
 
 
34  Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, 
in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-
005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
90
(ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 
2016;75:99-105.
 
 
 
36  Feldman SR. Development of a patient-reported outcome questionnaire for use in adults with 
moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. Journal of 
Dermatology & Dermatologic Surgery. 2016;20:19–26.
37  Mathias SD. Measurement properties of a patient-reported outcome measure assessing 
psoriasis severity: The psoriasis symptoms and signs diary. Journal of Dermatological 
Treatment. 2016;27(4):322-327.
38  Armstrong A, Puig L, Langley R, et al. Validation of psychometric properties and development 
of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase 
III 
clinical 
trial. 
Journal 
of 
Dermatological 
Treatment. 
2017: 
1-31. 
DOI: 
10.1080/09546634.2017.1364694.
39  Finlay, AY, Khan, GK: Dermatology Life Quality Index (DLQI): A simple practical measure 
for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47  Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized 
serum creatinine values in the modification of diet in renal disease study equation for 
estimating glomerular filtration rate. Ann Intern Med 2006;145(4):247–54. 
48  Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the 
general population. J Affect Disord. 2009;114(1-3):163-173.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
91
49  Dhingra SS, Kroenke K, Zack MM, Strine TW, Balluz LS. PHQ-8 Days: a measurement option 
for DSM-5 Major Depressive Disorder (MDD) severity. Population Health Metrics. 2011;9:11. 
doi:10.1186/1478-7954-9-11.
50  The Federal Register. Guidance for Industry- Suicidal ideation and behavior: prospective 
assessment 
of 
occurrence 
in 
clinical 
trials. 
(06-Aug-2012). 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidanc
es/UCM225130.pdf. Accessed 22-Mar-2018. 
51  Greist JH, Mundt JC, Gwaltney CJ, Jefferson JW, Posner K. Predictive value of baseline 
electronic Columbia–Suicide Severity Rating Scale (eC–SSRS) assessments for identifying 
risk of prospective reports of suicidal behavior during research participation. Innov Clin 
Neurosci. 2014;11(9–10):23–31.
52  Mundt JC, Greist JH, Jefferson JW, Federico M, Mann JJ, Posner K. Prediction of suicidal 
behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the 
electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 2013;74(9):887-893. 
53  Posner, K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm 
of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric 
Suicidal Risk Analysis of Antidepressants. Am J Psychiatry. 2007;164:1035-1043.
54  Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate 
pain in millimetres? Pain. 1997;72(1-2):95-7. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
92
11 
APPENDICES 
APPENDIX 1 
ABBREVIATIONS AND TRADEMARKS .............................................93 
APPENDIX 2 
STUDY GOVERNANCE CONSIDERATIONS ......................................97 
APPENDIX 3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING .............................105 
APPENDIX 4 
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ......................................................109 
APPENDIX 5 
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF PSORIASIS 
(sPGA) .....................................................................................................113 
APPENDIX 6 
PSORIASIS AREA AND SEVERITY INDEX (PASI) ..........................114 
APPENDIX 7 
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA) ..................................................................................................115 
APPENDIX 9 
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS (PGA-F) ..117 
APPENDIX 11 
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA) .......................................................................120 
APPENDIX 13 
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD) .....................122 
APPENDIX 14 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) ............................123 
APPENDIX 21 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE ....................................................................145 
APPENDIX 22 
EIGHT-ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8) ........146 
APPENDIX 23 
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS .........................................................................................147 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
93
APPENDIX 1 
ABBREVIATIONS AND TRADEMARKS 
Term
Definition
 
AE
adverse event
AEI
adverse event of interest
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
Anti-HCV
hepatitis C virus antibody
AST
aspartate aminotransferase
 
BID
twice daily
BMS
Bristol-Myers Squibb
BSA
body surface area
BUN
blood urea nitrogen
Cavg, ss
average concentration at steady state
CFR
Code of Federal Regulations
CI
confidence interval
CMH
Cochran-Mantel-Haenszel 
CK
creatine kinase
CT
computed tomography
 
CYP450
cytochrome P450
DILI
drug-induced liver injury
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
94
Term
Definition
DLQI
Dermatology Life Quality Index
DMC
Data Monitoring Committee
DNA
deoxyribonucleic acid
ECG
electrocardiogram
eCRF
electronic case report form
eC-SSRS
electronic Columbia-Suicide Severity Rating 
Scale
eGFR
Estimated Glomerular Filtration Rate
 
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GI
gastrointestinal
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus 
hCG
human chorionic gonadotropin
Hct
hematocrit
HCV
hepatitis C virus
HDL
high density lipoprotein
Hgb
hemoglobin
HIV
human immunodeficiency virus
hs-CRP
high-sensitivity C-reactive protein
IB
Investigator Brochure
ICF
informed consent form
IEC
Independent Ethics Committee
IFN
interferon
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
95
Term
Definition
IFNJ
interferon gamma
Ig
immunoglobulin
IGRA
interferon gamma release assay
IL
interleukin
IM
intramuscular
IMP
investigational medicinal product
IP
investigational product 
IRT
interactive response technology
ITT
intent-to-treat
IV
intravenous
JAK
Janus kinase
LDH
lactate dehydrogenase
LDL
low density lipoprotein
LOCF
last observation carried forward
LS
least-squares
LTBI
latent tuberculosis infection
MACE
Major Adverse Cardiovascular Events
MedDRA
Medical Dictionary for Regulatory Activities
mBOCF
modified baseline observation carried forward
NRI
nonresponder imputation
PASE
psoriatic arthritis screening and evaluation
PASI
Psoriasis Area and Severity Index
PD
pharmacodynamics
PE
physical examination
PHQ-8
Eight-Item Patient Health Questionnaire
PK
pharmacokinetics
 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
96
Term
Definition
pp-PGA
palmoplantar Physician’s Global Assessment
PPS
Per Protocol Set
PsA
psoriatic arthritis
PSSD
Psoriasis Symptoms and Signs Diary
QD
once daily
QOD
every other day
PGA-F
Physician Global Assessment- Fingernails
PUVA
Psoralens with ultraviolet A
RNA
ribonucleic acid 
SAE
serious adverse event
SIB
Suicidal Ideation and Behavior
sPGA
static Physician Global Assessment
ss-PGA
scalp specific Physician’s Global Assessment
STAT
signal transducer and activator of 
transcription
TB
tuberculosis
T4
thyroxine
T3
triiodothyronine
TEAE
treatment-emergent adverse event
 
TSH
thyroid-stimulating hormone
TNF
tumor necrosis factor 
TYK2
tyrosine kinase 2
ULN
upper limit of normal
UVB
ultraviolet B
WOCBP
women of childbearing potential
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
97
APPENDIX 2 
STUDY GOVERNANCE CONSIDERATIONS 
Regulatory and Ethical Considerations 
Good Clinical Practice 
This study will be conducted in accordance with: 
x
Good Clinical Practice (GCP)  
x
as defined by the International Council for Harmonisation (ICH) 
x
in accordance with the ethical principles underlying European Union Directive 2001/20/EC 
x
United States Code of Federal Regulations, Title 21, Part 50 (21CFR50)  
x
applicable local requirements. 
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive approval/favorable opinion by Institutional Review 
Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study. 
All potential serious breaches must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in connection with the study or the 
protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity 
of the subjects of the study or the scientific value of the study. 
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks. 
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment).  
Institutional Review Board/Independent Ethics Committee 
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The investigator 
or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates.  
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures. 
Compliance with the Protocol and Protocol Revisions 
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects.  
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
98
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s) the deviation or change will be submitted, as soon 
as possible to: 
x
IRB/IEC 
x
Regulatory Authority(ies), if applicable by local regulations (per national requirements) 
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS. 
If an amendment substantially alters the study design or increases the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment. 
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s). 
Financial Disclosure 
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study. 
Informed Consent Process 
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate.  
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the subject volunteers to participate.  
Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample 
informed consent form (ICF), which will include all elements required by ICH, GCP and 
applicable regulatory requirements. The sample ICF will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki. 
Investigators must: 
x
Provide a copy of the consent form and written information about the study in the language in 
which the subject is most proficient prior to clinical study participation. The language must be 
nontechnical and easily understood.  
x
Allow time necessary for subject or subject's legally acceptable representative to inquire about 
the details of the study. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
99
x
Obtain an informed consent signed and personally dated by the subject or the subject's legally 
acceptable representative and by the person who conducted the informed consent discussion.  
x
Obtain the IRB/IEC’s written approval/favorable opinion of the written ICF and any other 
information to be provided to the subjects, prior to the beginning of the study, and after any 
revisions are completed for new information. 
If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his or her 
informed consent during the study, consent must additionally be obtained from the subject. 
Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legally acceptable representative or legal guardian, 
of all pertinent aspects of the study and of any new information relevant to the subject's willingness 
to continue participation in the study. This communication should be documented.  
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records. 
For minors, according to local legislation, one or both parents or a legally acceptable representative 
must be informed of the study procedures and must sign the ICF approved for the study prior to 
clinical study participation. The explicit wish of a minor, who is capable of forming an opinion 
and assessing this information to refuse participation in, or to be withdrawn from, the clinical study 
at any time should be considered by the investigator.  
Minors who are judged to be of an age of reason must also give their written assent. 
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with his or her 
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The explicit wish of a subject who is unable to give his or 
her written consent, but who is capable of forming an opinion and assessing information to refuse 
participation in, or to be withdrawn from, the clinical study at any time should be considered by 
the investigator. 
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society. 
Source Documents 
The investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
100
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
AE tracking/reporting, protocol required assessments, and/or drug accountability records). 
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original.  
Study Treatment Records 
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a health authority. 
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:
x
amount received and placed in storage 
area
x
amount currently in storage area
x
label identification number or batch 
number
x
amount dispensed to and returned by each 
subject, including unique subject 
identifiers
x
amount transferred to another area/site for 
dispensing or storage
x
nonstudy disposition (eg, lost, wasted) 
x
amount destroyed at study site, if 
applicable
x
amount returned to BMS
x
retain samples for 
bioavailability/bioequivalence, if 
applicable 
x
dates and initials of person responsible for
Investigational Product 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
101
If
Then
dispensing/accountability, as per the 
Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced 
from the sites stock or commercial supply, or 
a specialty pharmacy)
The investigator or designee accepts 
responsibility for documenting traceability 
and study treatment integrity in accordance 
with requirements applicable under law and 
the SOPs/standards of the sourcing pharmacy.   
These records should include:
x
label identification number or batch 
number 
x
amount dispensed to and returned by each 
subject, including unique subject 
identifiers
x
dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the 
Delegation of Authority Form.
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements. 
Case Report Forms 
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study. 
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and paper Pregnancy Surveillance Form, respectively. If 
electronic SAE form is not available, a paper SAE form can be used. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s). 
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs.  
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
102
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task.  For electronic CRFs, review and approval/signature is completed electronically through the 
electronic data capture tool. The investigator must retain a copy of the CRFs including records of 
the changes and corrections. 
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the electronic data capture tool using the unique user account 
provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals. 
Monitoring 
Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of study records.  
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents: 
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential. 
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee.  
Records Retention 
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study. 
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed. 
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee.  
Return of Study Treatment 
For this study, study treatments (those supplied by BMS, a vendor or sourced by the investigator) 
such as partially-used study treatment containers, vials and syringes may be destroyed on site. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
103
If
Then
Study treatments supplied by BMS (including 
its vendors)
Any unused study treatments supplied by 
BMS can only be destroyed after being 
inspected and reconciled by the responsible 
Study Monitor unless study treatments 
containers must be immediately destroyed as 
required for safety, or to meet local 
regulations (eg, cytotoxics or biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied
by BMS (or its vendors) (examples include 
study treatments sourced from the sites stock 
or commercial supply, or a specialty 
pharmacy)
It is the investigator’s or designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met: 
x
On-site disposal practices must not expose humans to risks from the drug. 
x
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances. 
x
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request. 
x
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented. 
x
Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period. 
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers. 
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of nonstudy 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
104
Clinical Study Report and Publications 
A Signatory Investigator must be selected to sign the CSR. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria: 
x
External Principal Investigator designated at protocol development 
x
National Coordinating Investigator  
x
Study Steering Committee chair or their designee 
x
Subject recruitment (eg, among the top quartile of enrollers) 
x
Involvement in trial design 
x
Regional representation (eg, among top quartile of enrollers from a specified region or country) 
x
Other criteria (as determined by the study team) 
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing study site or investigator participation in the 
study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTA. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
105
APPENDIX 3 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING,
EVALUATING, FOLLOW-UP AND REPORTING 
Adverse Events
Adverse Event Definition:
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study drug, whether or not 
considered related to the study drug.
Events Meeting the AE Definition
x
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. Note that 
abnormal lab tests or other safety assessments should only be reported as AEs if the 
final diagnosis is not available. Once the final diagnosis is known, the reported term 
should be updated to be the diagnosis. 
x
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.
x
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
x
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
x
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose as a verbatim term (as reported by 
the investigator), should not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae and should specify "intentional overdose" as the 
verbatim term.
Events NOT Meeting the AE Definition
x
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads 
to the procedure is the AE.
x
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
106
DEFINITION OF SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met. 
Serious Adverse Events 
Serious Adverse Event Definition: Any untoward medical occurrence that, at any dose:
Results in death
Is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see note 
below)
Note: The following hospitalizations are not considered SAEs in BMS clinical studies: 
x
a visit to the emergency room or other hospital department <24 hours, that does not 
result in admission (unless considered an important medical or life-threatening event)
x
elective surgery, planned prior to signing consent
x
admissions as per protocol for a planned medical/surgical procedure
x
routine health assessment requiring admission for baseline/trending of health status 
(eg, routine colonoscopy)
x
medical/surgical admission other than to remedy ill health and planned prior to entry 
into the study. Appropriate documentation is required in these cases.
x
admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (eg, lack of housing, economic 
inadequacy, caregiver respite, family circumstances, administrative reason)
x
admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols)
Results in persistent or significant disability or permanent damage
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above). Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization. Potential drug-induced liver injury (DILI) is also considered an important 
medical event (see Section 8.2.8 for the definition of potential DILI). 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
107
Pregnancy and potential DILI must follow the same transmission timing and processes to BMS as 
used for SAEs (see Section 8.2.6 for reporting pregnancies).
Evaluating AEs and SAEs 
Follow-up of AEs and SAEs
Assessment of Intensity
The intensity of AEs is determined by a physician and will use the following levels:
x
Mild: An event that is easily tolerated by the subject, causing minimal discomfort, 
and not interfering with everyday activities.
x
Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.
x
Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utilized for 
rating the intensity of an event; and both AEs and SAEs can be assessed as severe.
Assessment of Causality
x
The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE. A “reasonable possibility of a relationship” 
conveys that there are facts, evidences, and/or arguments to suggest a causal 
relationship rather than a relationship cannot be ruled out.  
x
The investigator will use clinical judgment to determine the relationship.
x
Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.
x
The investigator will also consult the Investigator Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
x
For each AE/SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality.
x
There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Sponsor. However, it is very 
important that the investigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to Sponsor.
x
The investigator may change his/her opinion of causality in light of follow-up
information and send a SAE follow-up report with the updated causality 
assessment.
x
The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
108
If only limited information is initially available, follow-up reports are required. Note: 
Follow-up SAE reports must include the same investigator term(s) initially reported. 
If an ongoing SAE changes in its intensity or relationship to study drug or if new 
information becomes available, the SAE report must be updated and submitted within 
24 hours to BMS (or designee) using the same procedure used for transmitting the initial 
SAE report.
All SAEs must be followed to resolution or stabilization.
Reporting of SAEs to Sponsor or Designee
SAEs, whether related or not related to study drug, and pregnancies must be reported to 
 Drug Safety within 24 hours of awareness of the event.
SAEs must be recorded on the SAE Report Form. For studies capturing SAEs through 
electronic data capture, electronic submission is the required method for reporting. In the 
event the electronic system is unavailable for transmission, paper forms must be used and 
submitted immediately. When paper forms are used, the original paper forms are to remain 
on site.
Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
SAE Fax Number: 
Americas: 
Europe/East Asia-Pacific:
SAE Telephone Contact - For questions on SAE/pregnancy reporting, please call:
Americas: 
Europe/East Asia-Pacific: 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
109
APPENDIX 4 
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION 
DEFINITIONS 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy. 
Women in the following categories are not considered WOCBP 
x
Premenarchal 
x
Premenopausal female with 1 of the following: 

Documented hysterectomy 

Documented bilateral salpingectomy 

Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s review of the subject’s medical records, 
medical examination, or medical history interview. 
x
Postmenopausal female 

A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 45 
years in the absence of other biological or physiological causes. In addition, females under 
the age of 55 years must have a serum follicle-stimulating hormone, (FSH) level >40 
mIU/mL to confirm menopause. 
Note: Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their judgment 
in checking serum FSH levels.  
x
1-week minimum for vaginal hormonal products (rings, creams, gels) 
x
4-week minimum for transdermal products 
x
8-week minimum for oral products 
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is >40 mIU/ml at any time during the washout period, the woman can be considered 
postmenopausal. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
110
CONTRACEPTION GUIDANCE FOR FEMALE SUBJECTS OF CHILD BEARING 
POTENTIAL 
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 3 days after the end of study treatment, 
plus 30 days. 
Local laws and regulations may require use of alternative and/or additional contraception methods. 
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a
x
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulationb

oral 

intravaginal 

transdermal 
x
Progestogen-only hormonal contraception associated with inhibition of ovulationb

oral 

injectable 
Highly Effective Methods That Are User Independent
x
Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation b
x
Intrauterine device (IUD)c
x
Intrauterine hormone-releasing system (IUS)c
x
Bilateral tubal occlusion
x
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
111
x
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the subject.
x
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
x
WOCBP subjects who choose complete abstinence must continue to have pregnancy tests, 
as specified in Section 5.1
x
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP subjects chooses to forego complete abstinence 
NOTES: 
a  Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
subjects participating in clinical studies. 
b  Hormonal contraception may be susceptible to interaction with the study treatment, which may 
reduce the efficacy of the contraceptive method. Hormonal contraception is permissible only 
when there is sufficient evidence that the IMP and other study medications will not alter 
hormonal exposures such that contraception would be ineffective or result in increased 
exposures that could be potentially hazardous. In this case, alternative methods of 
contraception should be utilized. 
c  Intrauterine devices and intrauterine hormone-releasing systems are acceptable methods of 
contraception in the absence of definitive drug interaction studies when hormone exposures 
from intrauterine devices do not alter contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year when used consistently and correctly.
x
Male or female condom with or without spermicide.  Male and female condoms cannot be 
used simultaneously
x
Diaphragm with spermicide
x
Cervical cap with spermicide
x
Vaginal Sponge with spermicide
x
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
112
Unacceptable Methods of Contraception
x
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
x
Withdrawal (coitus interruptus).
x
Spermicide only
x
Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE SUBJECTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL. 
Male subjects with female partners of childbearing potential are eligible to participate if they agree 
to the following during the treatment and until the end of relevant systemic exposure. 
x
Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator. 
x
Male subjects are required to use a condom for study duration and until the end of relevant 
systemic exposure defined as 3 days after the end of treatment in the male subject. 
x
Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 3 days after the end of 
treatment in the male subject. 
x
Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 3 days after the end of treatment.  
x
Refrain from donating sperm for the duration of the study treatment and for 3 days after the 
end of treatment. 
COLLECTION OF PREGNANCY INFORMATION 
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 8.2.6 and APPENDIX 3. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
113
APPENDIX 5 
STATIC PHYSICIAN’S GLOBAL ASSESSMENT OF PSORIASIS 
(sPGA) 
The static PGA is used to determine the subject’s psoriasis lesions overall at a given time point. 
Overall lesions will be graded for erythema, induration, and scaling based on the scales below. 
The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA 
score. 
Characteristics
Score
Rating Score
Erythema (E)
(averaged over the whole body)
0 = No evidence of erythema, but post inflammatory 
hyper/hypopigmentation changes may be present
1 = Faint erythema
2 = Light red coloration
3 = Moderate red coloration 
4 = Bright red coloration
Induration (I)
(averaged over the whole body)
0 = No evidence of plaque elevation
1 = Minimal plaque elevation, barely palpable, = 0.25 mm
2 = Mild plaque elevation, slight but definite 
elevation, indistinct edge, = 0.5 mm
3 = Moderate plaque elevation, elevated with distinct edges, 
= 0.75 mm
4 = Severe plaque elevation, hard/sharp 
borders, ≥1 mm
Scaling (S)
(averaged over the whole body)
0 = No evidence of scaling
1 = Minimal; occasional fine scaling
2 = Mild; fine scale dominates
3 = Moderate; coarse scale predominates
4 = Severe; thick scale predominates
E + I + S = / 3 = (Total Average)
Physician’s Static Global Assessment based upon above Total Average 
0 = Clear, except for residual discoloration  
1 = Almost clear -majority of lesions have individual scores for E + I + S / 3 that averages 1  
2 = Mild -majority of lesions have individual scores for E + I + S / 3 that averages 2  
3 = Moderate -majority of lesions have individual scores for E + I + S / 3 that averages 3  
4 = Severe -majority of lesions have individual scores for E + I + S / 3 that averages 4  
Note: Scores should be rounded to the nearest whole number. If total ≤1.49, score = 1; if 
total ≥1.50, score = 2.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
114
APPENDIX 6 
PSORIASIS AREA AND SEVERITY INDEX (PASI) 
Psoriasis Area and Severity Index (PASI); a quantitative rating scale for measuring the severity of psoriatic 
lesions based on area coverage and plaque appearance. Please complete all sections of the table. 
Plaque Characteristic
Rating score
Body region (and weighting factor)
Head
Upper Extremities
Trunk
Lower Extremities
Erythema (Redness)
0 = None
1 = Slight
2 = Moderate
3 = Severe
4 = Very severe
Infiltration (Thickness)
Desquamation (Scaling)
Add together each of the 3 scores for each of the body regions to give 4 separate sub totals.
Sub Totals A1 =
A2 =
A3 =
A4 =
Multiply each subtotal by amount of body surface area represented by that region i.e. A1 x 0.1 for head, A2 x 0.2 for upper 
extremities, A3 x 0.3 for trunk, A4 x 0.4 for lower extremities to give a value B1, B2, B3 and B4 for each body region respectively
A1 x 0.1 = B1
A2 x 0.2 = B2
A3 x 0.3 = B3
A4 x 0.4 = B4
B1 =
B2 =
B3 =
B4 =
Degree of involvement 
as % for each body 
region affected; (score
each region with score 
between 0-6)
0 = None
1 = 1-9 %
2 = 10-29%
3 = 30-49%
4 = 50 -69%
5 = 70-89%
6 = 90-100%
For each body region multiply sub total B1, B2, B3 and B4 by the score (0-6) of the % of body region involved to give 4 subtotals 
C1, C2, C3 and C4
B1 x score = C1
B2 x score = C2
B3 x score = C3
B4 x score = C4
C1 =
C2 =
C3 =
C4 =
The patient’s PASI score is the sum of C1 + C2 + C3 + C4
PASI=
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
115
APPENDIX 7 
SCALP SPECIFIC PHYSICIAN’S GLOBAL ASSESSMENT 
(ss-PGA) 
Please rate overall scalp psoriasis severity by selecting the overall score based on the following 
rating scale: 
Score
Category
Description
0
Absence of 
Disease
No evidence of redness, no evidence of thickness, and no 
evidence of scaliness on the scalp
1
Very Mild Disease
The overall clinical picture consists of flat lesions with barely 
perceptible erythema, with or without a trace of overlying fine 
scale
2
Mild Disease
The overall clinical picture consists of lesions with mild 
erythema, slight, but definite, thickness, and a thin scale layer
3
Moderate Disease
The overall clinical picture consists of lesions with moderate 
erythema, a moderate thickness, and a moderate scaled layer
4
Severe Disease
The overall clinical picture consists of lesions with bright 
erythema, severe thickness, and a severe, coarse thick scale 
layer
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
116
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
117
APPENDIX 9 
PHYSICIAN’S GLOBAL ASSESSMENT-FINGERNAILS (PGA-F)
For this assessment in subjects with psoriasis fingernail involvement, the overall condition of the 
fingernails is rated by the investigator on a 0-4 (5-point) scale. The overall score assigned based 
on the higher of the nail bed/nail matrix score: 
Nail Bed Signs
Nail Matrix Signs
Clear
0
Onycholysis- consistent with a normal nail
AND
Hyperkeratosis- none
AND
Splinter Hemorrhages-consistent with non-psoriatic splinter 
hemorrhages
AND
Nail Bed Erythema- none
No non-psoriatic nail plate 
irregularities including 
pitting, crumbling, Beau’s 
lines, senile onychorrhexis, 
and non-psoriatic 
leukonychia
Minimal
1
Onycholysis- < 10% involved on all nails
OR
Hyperkeratosis- present, but barely detectable elevation of 
nail plate
OR
Nail Bed Erythema- faint
AND
Splinter Hemorrhages- consistent with non-psoriatic splinter 
hemorrhages
No more than 5 pits or 
psoriatic leukonychia on any 
nail
AND
No crumbling
Mild
2
Onycholysis- >10% on five or more nails
OR
Hyperkeratosis- present with mild elevation of nail plate
OR
Splinter Hemorrhages- present on four or fewer nails
OR
Nail Bed Erythema- mild
Five or more nails with mild 
pitting (eg, >10 pits/nail) or 
psoriatic leukonychia
AND
No crumbling
Moderate
3
Onycholysis- >30% on at least one nail
OR
Hyperkeratosis- present with moderate elevation of nail plate
OR
Splinter Hemorrhages- scattered and present on five or more 
nails
OR
Nail Bed Erythema- moderate
Five or more nails with 
moderate pitting (eg, >25 
pits/nail)
AND
≤25% crumbling on any nails
Severe
4
Onycholysis- >50% on at least one nail
OR
Hyperkeratosis- present with severe elevation of nail plate
OR
Splinter Hemorrhages- numerous and present on five or more 
nails
OR
Nail Bed Erythema- severe
Five or more nails with 
severe pitting (>50 pits/nail)
OR
>25% crumbling on any nail
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
118
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
119
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
120
APPENDIX 11 
PALMOPLANTAR PSORIASIS PHYSICIAN’S GLOBAL 
ASSESSMENT (pp-PGA) 
Palmoplantar (including finger and toe surfaces) psoriasis lesions are evaluated by the investigator 
based on overall severity, then scored on the following 5-point scale: 
Score
Category
Description
0
Clear
No signs of plaque psoriasis
1
Almost 
Clear
Just perceptible erythema and just perceptible scaling
2
Mild
Light pink erythema, with minimal scaling with or without pustules
3
Moderate
Dull red, clearly distinguishable erythema with diffuse scaling, some 
thickening of the skin, with or without fissures, with or without pustule 
formation
4
Severe
Deep, dark red erythema with obvious and diffuse scaling and 
thickening as well as numerous fissures with or without pustule 
formation
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
121
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
122
APPENDIX 13 
PSORIASIS SYMPTOMS AND SIGNS DIARY (PSSD) 
Please answer each question to the best of your ability. There are no right or wrong answers. Please 
pay close attention to the time period of interest. These questions ask you to think about the past 
24 hours. Please complete the diary at the same time every day.
Individuals with psoriasis may experience a range of symptoms. Please indicate how severe each 
of the following skin symptoms was in the past 24 hours. Please select only one number for  each 
item on the 0 to 10 scale (0=Absent and 10= Worst imaginable).
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
123
APPENDIX 14 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
Hospital No: 
Date: 
Score: 
Name: 
Diagnosis: 
Address: 
The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE 
LAST WEEK. Please tick one box for each question. 
Please check you have answered EVERY question. Thank you 
1.
Over the last week, how itchy, sore, painful or stinging has your skin been?
Very much 
A lot
A little 
Not at all
2.
Over the last week, how embarrassed or self-conscious have you been because 
of your skin?
Very much 
A lot
A little 
Not at all
3.
Over the last week, how much has your skin interfered with you going shopping 
or looking after your home or garden?
Very much 
A lot
A little 
Not at all
Not relevant
4.
Over the last week, how much has your skin influenced the clothes you wear?
Very much 
A lot
A little 
Not at all
Not relevant
5.
Over the last week, how much has your skin affected any social or leisure activities? Very much 
A lot
A little 
Not at all
Not relevant
6.
Over the last week, how much has your skin made it difficult for you to do any sport? Very much 
A lot
A little 
Not at all
Not relevant
7.
Over the last week, has your skin prevented you from working or studying?
yes 
no
Not relevant
If “No”, over the last week how much has your skin been a problem at work or
studying?
A lot 
A little
Not at all
8.
Over the last week, how much has your skin created problems with your partner 
or any of your close friends or relatives?
Very much 
A lot
A little 
Not at all
Not relevant
9.
Over the last week, how much has your skin caused any sexual difficulties?
Very much 
A lot
A little 
Not at all
Not relevant
10. Over the last week, how much of a problem has the treatment for your skin been, 
for example by making your home messy, or by taking up time?
Very much 
A lot
A little 
Not at all
Not relevant
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
124
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
125
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
126
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
127
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
128
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
129
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
130
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
131
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
132
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
133
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
134
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
135
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
136
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
137
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
138
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
139
Approved
1.0
v
Approved
2.0
v

Cli nical Pr ot oc ol 
I M 0 1 1 0 4 6 
B M S- 9 8 6 1 6 5
T Y K 2 I n hi bit or 
1 7 Dec 2 0 1 9, Fi nal A p pr o ve d v 6. 0 
B M S C o nfi de ntial 
1 4 0
A p p r o v e d 
1 . 0
v
A p p r o v e d
2 . 0
v

Cli nical Pr ot oc ol 
I M 0 1 1 0 4 6 
B M S- 9 8 6 1 6 5
T Y K 2 I n hi bit or 
1 7 Dec 2 0 1 9, Fi nal A p pr o ve d v 6. 0 
B M S C o nfi de ntial 
1 4 1
A p p r o v e d 
1 . 0
v
A p p r o v e d
2 . 0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
142
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
143
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
144
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
145
APPENDIX 21 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION 
(PASE) QUESTIONNAIRE 
PSORIATIC ARTHRITIS SCREENING AND EVALUATION (PASE) QUESTIONNAIRE 
Please circle or mark ONLY ONE of the five choices on the following 15 questions. The answers to these 
questions will help us better understand your symptoms. This should take about 5-6 minutes to complete. 
Thank you for your time. 
Symptoms sub-scale
Strongly 
Disagree
Disagree
Neutral
Agree
Strongly 
Agree
1.
I feel tired for most of the day
1
2
3
4
5
2.
My joints hurt
1
2
3
4
5
3.
My back hurts
1
2
3
4
5
4.
My joints become swollen
1
2
3
4
5
5.
My joints feel ‘hot’
1
2
3
4
5
6.
Occasionally, an entire finger or toe becomes 
swollen, making it look like a ‘sausage’
1
2
3
4
5
7.
I have noticed that the pain in my joints moves 
from one joint to another, eg my wrist will hurt for a few 
days then my knee will hurt and so on.
1
2
3
4
5
SYMPTOM SCORE (Max 35)
Add scores for questions 1-7 and write in box A
A.
Function sub-scale
Strongly 
Disagree
Disagree
Neutral
Agree
Strongly 
Agree
8.
I feel that my joint problems have affected my 
ability to work
1
2
3
4
5
9.
My joint problems have affected my ability to care 
for myself, eg getting dressed or brushing my teeth
1
2
3
4
5
10. I have had trouble wearing rings on my fingers or 
my watch
1
2
3
4
5
11. I have had trouble getting into or out of a car
1
2
3
4
5
12. I am unable to be as active as I used to be
1
2
3
4
5
13. I feel stiff for more than 2 hours after waking up in 
the morning
1
2
3
4
5
14. The morning is the worst time of day for me
1
2
3
4
5
15. It takes me a few minutes to get moving to the best 
of my ability, any time of the day
1
2
3
4
5
FUNCTION SCORE (Max 40)
Add scores for questions 8-15 and write in box B
B.
TOTAL PASE SCORE (Max 75)
Add scores in boxes A and B and write in box C
C.
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
146
APPENDIX 22 
EIGHT-ITEM PATIENT HEALTH QUESTIONNAIRE (PHQ-8)
The eight-item Patient Health Questionnaire depression scale is established as a valid 
self-administered diagnostic and severity measure for depressive disorders. It consists of 8 
different questions, with an answer scale from 0-3. The overall score is determined by adding up 
each of the individual answers from each question.  
Scoring interpretation is as follows: 0-4 no significant depressive symptoms, 5-9 mild depressive 
symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, 
and 20-24 severe depressive symptoms 
Over the last 2 weeks, how often have you 
been bothered by any of the following 
problems? 
Not at all
Several 
Days
More than 
half the 
days
Nearly 
every day
1. Little interest or pleasure in doing things
0
1
2
3
2. Feeling down, depressed, or hopeless
0
1
2
3
3. Trouble falling or staying asleep, or 
sleeping too much
0
1
2
3
4. Feeling tired or having little energy
0
1
2
3
5. Poor appetite or over eating
0
1
2
3
6. Feeling bad about yourself, or that you 
are a failure, or have let yourself or your 
family down
0
1
2
3
7. Trouble concentrating on things, such as 
reading the newspaper, or watching 
television
0
1
2
3
8. Moving or speaking so slowly that other 
people could have noticed? Or the 
opposite, being so fidgety or restless that 
you have been moving around a lot more 
than usual
0
1
2
3
Total Score: 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
147
APPENDIX 23 
SUICIDAL IDEATION AND BEHAVIOR CATEGORIES AND 
DEFINITIONS 
Suicidal Ideation 
Passive suicidal ideation: wish to be dead 
Patient has thoughts about a wish to be dead or not alive anymore, or wish to fall asleep 
and not wake up. 
Active suicidal ideation: nonspecific (no method, intent, or plan) 
General nonspecific thoughts of wanting to end one’s life or commit suicide (eg, “I’ve 
thought about killing myself”) without general thoughts of ways to kill oneself/associated 
methods, intent, or plan during the assessment period. 
Active suicidal ideation: method, but no intent or plan 
Patient has thoughts of suicide and has thought of at least one method during the assessment 
period.  This situation is different than a specific plan with time, place, or method details 
worked out (eg, thought of method to kill self but not a specific plan). Includes person who 
would say, “I thought about taking an overdose but I never made a specific plan as to when, 
where, or how I would actually do it . . . and I would never go through with it.”
Active suicidal ideation: method and intent, but no plan 
Active suicidal thoughts of killing oneself, and patient reports having some intent to act on 
such thoughts, as opposed to “I have the thoughts but I definitely will not do anything about 
them.”
Active suicidal ideation:  method, intent, and plan 
Thoughts of killing oneself with details of plan fully or partially worked out and patient 
has some intent to carry it out (ie, some degree of intent is implicit in the concept of plan). 
Suicidal Behavior 
Completed suicide 
A self-injurious behavior that resulted in fatality and was associated with at least some 
intent to die as a result of the act. Evidence that the individual intended to kill him- or 
herself, at least to some degree, can be explicit or inferred from the behavior or 
circumstance. 
Suicide attempt 
A potentially self-injurious behavior, associated with at least some intent to die as a result 
of the act. Evidence that the individual intended to kill him- or herself, at least to some 
degree, can be explicit or inferred from the behavior or circumstance. A suicide attempt 
may or may not result in actual injury. 
Approved
1.0
v
Approved
2.0
v

Clinical Protocol 
IM011046 
BMS-986165
TYK2 Inhibitor 
17 Dec 2019, Final Approved v6.0 
BMS Confidential 
148
Interrupted suicide attempt 
When the person is interrupted (by an outside circumstance) from starting a potentially 
self-injurious act (if not for that, actual attempt would have occurred). 
Aborted suicide attempt 
When person begins to take steps toward making a suicide attempt, but stops before 
actually engaging in any self-destructive behavior. Examples are similar to interrupted 
attempts, except that the individual stops before being stopped by something else. 
Preparatory acts toward imminent suicidal behaviors 
This category can include anything beyond a verbalization or thought, but it stops short of 
a suicide attempt, an interrupted suicide attempt, or an aborted suicide attempt. This might 
include behaviors related to assembling a specific method (eg, buying pills, purchasing a 
gun) or preparing for one’s death by suicide (eg, giving things away, writing a suicide 
note).
Self-Injurious Behavior Without Suicidal Intent 
Self-injurious behavior associated with no intent to die. The behavior is intended purely for other 
reasons, either to relieve distress (often referred to as self-mutilation [eg, superficial cuts or 
scratches, hitting or banging, or burns]) or to effect change in others or the environment. 
Approved
1.0
v
Approved
2.0
v